{"abstract_id": 3392, "endpoint_id": 168, "truth": 1, "pred": 1, "blended_prob": 0.8134482758620689, "llm_prob": 0.85, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Small sample size (n=24) and single\u2011arm design may limit robustness"], "green": []}, "rationale": "The trial met its predefined success criterion by reporting an overall response rate of 75%, which exceeds the 60% threshold for further study. Although the single\u2011arm design and modest enrollment introduce uncertainty, the endpoint is clearly defined and achieved.", "citations": [{"title": "Phase II trial of cisplatin\u2011RT with pembrolizumab in vulvar cancer (NCT04430699)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04430699"}, {"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 2892, "endpoint_id": 125, "truth": 1, "pred": 1, "blended_prob": 0.77, "llm_prob": 0.7, "base_prob": 0.875, "base_note": "Base rate from phase_3_plus / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for safety outcome not found in retrieved external sources; relies on trial abstract text."], "green": []}, "rationale": "The trial reports that no new safety signals emerged, satisfying the decision rule. The large randomized phase\u20113 design with over 1,000 patients provides a robust safety assessment, but external citations are lacking.", "citations": []}
{"abstract_id": 1698, "endpoint_id": 100, "truth": 1, "pred": 1, "blended_prob": 0.879448275862069, "llm_prob": 0.96, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target fgfr1-3 tyrosine kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": ["robust primary endpoint data"]}, "rationale": "The single\u2011arm phase\u202f2 basket trial reports an objective response rate by independent central review of 20.0% in Group\u202fB with a one\u2011sided p\u2011value of 0.0362, which is below the 0.05 threshold required to reject the null hypothesis of \u22645% response, thus meeting the primary endpoint.", "citations": [{"title": "Tasurgratinib phase\u202f2 basket trial (NCT04962867) \u2013 primary endpoint results", "url": "https://clinicaltrials.gov/ct2/show/NCT04962867"}]}
{"abstract_id": 4719, "endpoint_id": 247, "truth": 1, "pred": 1, "blended_prob": 0.6, "llm_prob": 0.6, "base_prob": 0.6, "base_note": "Base rate from unknown / co-primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Limited external citation for biomarker findings; reliance on trial summary details"], "green": []}, "rationale": "The trial reports significant associations between immunological biomarkers (Th7R and Th2) and progression\u2011free and overall survival for osimertinib, meeting the exploratory co\u2011primary endpoint, though the sample size is modest (95 patients).", "citations": []}
{"abstract_id": 3679, "endpoint_id": 190, "truth": 1, "pred": 1, "blended_prob": 0.7, "llm_prob": 0.7, "base_prob": 0.7, "base_note": "Base rate from phase_2 / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for irAE rates comes from trial details, not from retrieved external sources."], "green": []}, "rationale": "The trial reports immune-related adverse events in 6.7% of the toripalimab arm versus 0% in the control arm with a p\u2011value of 0.058, which does not meet the significance threshold (p\u202f\u2265\u202f0.05) required to claim a difference in harm.", "citations": []}
{"abstract_id": 1825, "endpoint_id": 271, "truth": 1, "pred": 1, "blended_prob": 0.635, "llm_prob": 0.6, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target wee1 kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["insufficient citation evidence for etoposide exposure outcome"], "green": []}, "rationale": "The trial abstract reports no major changes in etoposide exposure across Debio 0123 dose levels, indicating the decision rule of unchanged exposure is satisfied, but the lack of supporting citations from the retrieved evidence lowers confidence.", "citations": []}
{"abstract_id": 1288, "endpoint_id": 76, "truth": 1, "pred": 1, "blended_prob": 0.5175000000000001, "llm_prob": 0.3, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target ep4 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient direct evidence from retrieved sources to confirm absence of treatment\u2011related serious or grade\u202f>\u202f3 adverse events."], "green": []}, "rationale": "The trial abstract states no treatment\u2011related serious or grade\u202f>\u202f3 adverse events, satisfying the safety decision rule, but this outcome is not present in any of the retrieved evidence snippets, limiting confidence in the assessment.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 6202, "endpoint_id": 48, "truth": 1, "pred": 1, "blended_prob": 0.8780000000000001, "llm_prob": 0.88, "base_prob": 0.875, "base_note": "Base rate from phase_3_plus / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target thrombopoietin receptor not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Citation for the specific endpoint result not found in retrieved evidence"], "green": []}, "rationale": "The trial randomized 165 patients (2:1) to romiplostim vs placebo and reported a median time to first platelet response of 1.1 weeks vs 2.1 weeks with a p\u2011value <0.001, satisfying the superiority decision rule (p < alpha). Sample size and randomization are adequate for a phase\u202f3 endpoint assessment.", "citations": []}
{"abstract_id": 2329, "endpoint_id": 122, "truth": 0, "pred": 1, "blended_prob": 0.8521176470588236, "llm_prob": 0.93, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The exploratory analysis reported a log\u2011rank P value of 0.519 for PFS comparison between DDR\u2011mutated and non\u2011mutated patients, which does not meet the predefined significance threshold (p\u202f<\u202f0.05). The sample size is small (16 evaluable patients), further limiting statistical power.", "citations": [{"title": "NCT05832892 \u2013 Phase 1b/2 trial of surufatinib + KN046 + GnP in advanced pancreatic cancer", "url": "https://clinicaltrials.gov/ct2/show/NCT05832892"}]}
{"abstract_id": 3719, "endpoint_id": 287, "truth": 1, "pred": 1, "blended_prob": 0.647, "llm_prob": 0.62, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for the specific emotional\u2011well\u2011being result is not present in the retrieved citations; inference relies on trial summary alone."], "green": []}, "rationale": "The trial reports a statistically significant improvement in emotional well\u2011being (p\u202f=\u202f0.045) meeting the pre\u2011specified p\u2011value threshold, but the supporting data are not found in the retrieved evidence, reducing confidence.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 2345, "endpoint_id": 124, "truth": 1, "pred": 1, "blended_prob": 0.867448275862069, "llm_prob": 0.94, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["PD-1 target has established approvals"]}, "rationale": "The single\u2011arm phase\u202fII trial enrolled 37 patients and reported a confirmed ORR of 67.6%, exceeding the predefined threshold of 68% (23 responses) required by the Simon's minimax design, thus meeting the primary endpoint.", "citations": [{"title": "Phase II trial of serplulimab + HLX04 with nab\u2011paclitaxel/gemcitabine followed by mFOLFOX in advanced pancreatic cancer", "url": "http://www.clinicaltrials.gov/ct2/show/NCT06393166"}]}
{"abstract_id": 1618, "endpoint_id": 96, "truth": 1, "pred": 1, "blended_prob": 0.5877777777777777, "llm_prob": 0.35, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target braf has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Insufficient direct evidence from retrieved sources to confirm that the MTD was identified according to the 3+3 design."], "green": []}, "rationale": "The trial enrolled 17 patients across five dose levels using a 3+3 design and reported no dose\u2011limiting toxicities, but it does not state that a maximum tolerated dose was established; thus the primary endpoint of determining MTD is not clearly met, especially given the small sample size and lack of explicit MTD determination.", "citations": []}
{"abstract_id": 6278, "endpoint_id": 49, "truth": 1, "pred": 1, "blended_prob": 0.5885714285714285, "llm_prob": 0.6, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for the dyspnea p\u2011value is only in the trial description, not in the retrieved external sources; reliance on internal data reduces confidence."], "green": []}, "rationale": "The trial reports a dyspnea p\u2011value of 0.02 favoring the cannabis extract, which meets the predefined superiority threshold (p\u202f<\u202f0.05) for this secondary endpoint, but the supporting evidence is limited to the trial abstract rather than independent retrieved citations.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 1292, "endpoint_id": 71, "truth": 1, "pred": 1, "blended_prob": 0.8422000000000001, "llm_prob": 0.93, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["citation limited to trial summary"], "green": ["primary endpoint clearly defined and met"]}, "rationale": "The phase\u20111 single\u2011arm study of LB1410 reported no dose\u2011limiting toxicities across all dose cohorts, directly satisfying the predefined decision rule of absence of DLTs at the tested doses. The sample size (79 treated patients) is adequate for a phase\u20111 safety assessment, and the endpoint is robustly captured as the primary safety objective.", "citations": []}
{"abstract_id": 1052, "endpoint_id": 54, "truth": 1, "pred": 1, "blended_prob": 0.6950000000000001, "llm_prob": 0.7, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for statistical significance is based on trial summary details rather than independent retrieved citations"], "green": []}, "rationale": "The CATNON phase III trial reports a median overall survival of 12.5 years for patients receiving adjuvant temozolomide with a p\u2011value <0.0001, satisfying the p\u202f<\u202f0.05 criterion for statistical significance of the median OS estimate.", "citations": []}
{"abstract_id": 1598, "endpoint_id": 90, "truth": 1, "pred": 1, "blended_prob": 0.6541176470588235, "llm_prob": 0.6, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target msln not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size", "no direct citation from retrieved evidence"], "green": []}, "rationale": "The trial reports that A2B694 was detected in peripheral blood of all five participants, satisfying the predefined decision rule for CAR T expansion. However, the evidence is based on a very small cohort and the supporting data are not present in the retrieved external sources, reducing confidence.", "citations": []}
{"abstract_id": 6221, "endpoint_id": 44, "truth": 0, "pred": 1, "blended_prob": 0.622, "llm_prob": 0.62, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Limited citation support for QoL data; QoL result derived from trial abstract not present in retrieved evidence list."], "green": []}, "rationale": "The secondary QoL endpoint reported a between\u2011group difference of \u20131.50 points with a 95% CI of \u20135.91 to 2.91, which includes zero, so the superiority criterion is not met. The sample size (n=105 ITT) is modest but sufficient for the reported analysis.", "citations": [{"title": "Randomized trial of 3\u2011week vs 6\u2011week corticosteroid treatment for mild immune\u2011related pneumonitis (jRCTs051220082)", "url": "N/A"}]}
{"abstract_id": 291, "endpoint_id": 13, "truth": 0, "pred": 1, "blended_prob": 0.8041176470588236, "llm_prob": 0.85, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cdk4/6 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["No direct citation from retrieved evidence supporting the specific trial result; inference based on trial details."], "green": []}, "rationale": "The trial reports that PAM50 analysis in 75 patients showed no significant correlation between intrinsic subtype and efficacy, indicating the exploratory endpoint was not met. Sample size is modest but sufficient for the analysis, and the result is clearly stated.", "citations": []}
{"abstract_id": 1941, "endpoint_id": 110, "truth": 1, "pred": 1, "blended_prob": 0.61, "llm_prob": 0.6, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["The specific MPR rate data and p\u2011value are not present in the retrieved citations, creating uncertainty."], "green": []}, "rationale": "The trial reports an MPR rate of 68.3% versus 43.9% with a p\u2011value of 0.026, which satisfies the superiority criterion (p<0.05). However, because the retrieved evidence does not include these figures, confidence in the assessment is moderated.", "citations": []}
{"abstract_id": 3905, "endpoint_id": 200, "truth": 1, "pred": 1, "blended_prob": 0.743, "llm_prob": 0.78, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Limited sample size (n=10) and single\u2011arm design; no external validation"], "green": []}, "rationale": "The single\u2011arm study of ten high\u2011risk APL patients reported that no participant experienced severe mucositis (Grade\u202f3/4), satisfying the decision rule. However, the small cohort and lack of a comparator limit the robustness of this conclusion.", "citations": []}
{"abstract_id": 2747, "endpoint_id": 282, "truth": 1, "pred": 1, "blended_prob": 0.8776923076923077, "llm_prob": 0.95, "base_prob": 0.7692307692307693, "base_note": "Base rate from phase_2 / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target tyrosine kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The trial explicitly reports that the Data and Safety Monitoring Board found no new and unexpected serious adverse events, satisfying the predefined toxicity decision rule for this secondary endpoint.", "citations": [{"title": "CABONEN study interim analysis \u2013 safety outcomes", "url": "https://clinicaltrials.gov/ct2/show/NCT05138952"}]}
{"abstract_id": 1318, "endpoint_id": 79, "truth": 1, "pred": 1, "blended_prob": 0.7741176470588236, "llm_prob": 0.8, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for the statistical significance of the absolute CD4+ T lymphocyte count is based on trial details not present in the retrieved literature snippets."], "green": []}, "rationale": "The randomized trial comparing CCRT+tislelizumab versus CCRT alone reported a significant increase in absolute CD4+ T lymphocyte count (p = 0.047), meeting the predefined significance threshold (p < 0.05) despite the modest sample size (53 patients).", "citations": []}
{"abstract_id": 107, "endpoint_id": 172, "truth": 0, "pred": 1, "blended_prob": 0.8041176470588236, "llm_prob": 0.85, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Key efficacy data (P=0.051 for CCND1 amplification) not present in retrieved citations"], "green": []}, "rationale": "The trial reports a non\u2011significant negative trend of CCND1 amplification on pCR (P=0.051), which exceeds the 0.05 threshold required for statistical significance. Despite a high overall tpCR rate, the specific biomarker analysis does not meet the decision rule, indicating the endpoint is not positively met.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 15, "endpoint_id": 330, "truth": 1, "pred": 1, "blended_prob": 0.7925714285714285, "llm_prob": 0.94, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The randomized phase\u20113 trial reported Grade\u202f3/4 gastrointestinal toxicities of 33.3% vs 4.5% (p\u202f=\u202f0.015) favoring the paclitaxel\u2011platinum arm, meeting the pre\u2011specified significance threshold (p\u202f<\u202f0.05) despite the modest sample size (49 patients).", "citations": []}
{"abstract_id": 41, "endpoint_id": 319, "truth": 1, "pred": 1, "blended_prob": 0.6009230769230769, "llm_prob": 0.6, "base_prob": 0.7692307692307693, "base_note": "Base rate from phase_2 / secondary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["insufficient direct evidence for 2nd DCR result"], "green": []}, "rationale": "The trial reports a 2nd disease control rate of 55.7% with panitumumab versus 37.3% with regorafenib, yielding an odds ratio of 2.17 and a p-value of 0.02, which satisfies the superiority hypothesis (p < 0.05). Although the analysis set is modest (75 vs 70 patients), the statistically significant difference supports the endpoint claim.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 6278, "endpoint_id": 50, "truth": 1, "pred": 1, "blended_prob": 0.6185714285714285, "llm_prob": 0.65, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Limited direct evidence for the insomnia endpoint; p\u2011value information comes from trial description, not from retrieved external sources."], "green": []}, "rationale": "The trial reports a statistically significant improvement in insomnia (p\u202f=\u202f0.01) favoring the cannabis extract, meeting the superiority threshold of p\u202f<\u202f0.05 for this secondary endpoint, despite the small sample size (n=40).", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 2248, "endpoint_id": 114, "truth": 1, "pred": 1, "blended_prob": 0.5705714285714285, "llm_prob": 0.57, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for perioperative morbidity difference is not directly cited from retrieved sources"], "green": []}, "rationale": "The randomized phase III trial reports postoperative morbidity rates of 33.3% vs 32% for neoadjuvant versus direct surgery arms, indicating no statistically significant difference, thus meeting the decision rule of no significant harm. However, the specific morbidity data are not present in the retrieved evidence, reducing confidence.", "citations": []}
{"abstract_id": 1633, "endpoint_id": 98, "truth": 0, "pred": 1, "blended_prob": 0.5554482758620689, "llm_prob": 0.42, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target erbb2/3 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Evidence for the OC cohort disease control outcome relies on trial description rather than retrieved literature; sample size is small and the result is not statistically significant."], "green": []}, "rationale": "The OC cohort enrolled 28 patients and reported a disease control (DC) rate of 25%, which corresponds to fewer than the required 7 of 28 patients to reject the null hypothesis; the study authors state the null DC rate was not rejected (p=0.29), indicating the primary endpoint was not met. The small cohort size and borderline result reduce confidence.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 5217, "endpoint_id": 12, "truth": 1, "pred": 1, "blended_prob": 0.6975, "llm_prob": 0.6, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for the safety outcome relies on trial details not present in the retrieved citations; citation support is weak."], "green": []}, "rationale": "The trial enrolled 22 patients and observed a single dose\u2011limiting toxicity (grade\u202f3 enterocolitis) at the highest dose, indicating an acceptable safety profile that allowed establishment of the RP2D, thus meeting the primary safety endpoint despite limited citation support.", "citations": []}
{"abstract_id": 4719, "endpoint_id": 243, "truth": 0, "pred": 1, "blended_prob": 0.785, "llm_prob": 0.85, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Evidence for the OS p\u2011value is only from the trial abstract provided in the prompt, not from the retrieved external sources; citation strength is limited."], "green": []}, "rationale": "The phase\u202fII randomized trial enrolled 95 patients (47 afatinib, 48 osimertinib) and reported median OS of 38.8\u202fmonths vs not reached, with a hazard ratio of 1.15 (95%\u202fCI 0.64\u20132.05) and a p\u2011value of 0.64, which does not meet the predefined significance threshold of p\u202f<\u202f0.05.", "citations": [{"title": "Phase II randomized trial of afatinib versus osimertinib in Japanese EGFR\u2011mutant NSCLC (jRCTs031190221)", "url": "N/A"}]}
{"abstract_id": 6202, "endpoint_id": 47, "truth": 1, "pred": 1, "blended_prob": 0.89, "llm_prob": 0.95, "base_prob": 0.8, "base_note": "Base rate from phase_3_plus / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target thrombopoietin receptor not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The phase\u20113 randomized trial enrolled 165 patients (109 romiplostim, 56 placebo) and demonstrated that 84% of romiplostim\u2011treated patients versus 36% of placebo patients achieved the primary endpoint, yielding an odds ratio of 10.2 (95%\u202fCI\u202f4.6\u201122.5) with P\u202f<\u202f0.001, thereby satisfying the superiority decision rule.", "citations": []}
{"abstract_id": 3123, "endpoint_id": 150, "truth": 1, "pred": 1, "blended_prob": 0.7275, "llm_prob": 0.65, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target parp, ezh2 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Limited direct evidence linking RP2D as a primary endpoint in early\u2011phase oncology trials"], "green": []}, "rationale": "The trial is a phase 1a/1b dose\u2011escalation study where the primary objective is to define the recommended phase 2 dose using a 3+3 design, which is a standard approach for early\u2011phase oncology trials; thus the RP2D endpoint is appropriate despite the lack of specific citation in the retrieved evidence.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 209, "endpoint_id": 258, "truth": 1, "pred": 1, "blended_prob": 0.7077777777777778, "llm_prob": 0.55, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cyclin dependent kinase 4/6, poly-adp-ribose polymerase (parp) not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Evidence for the specific DLT incidence outcome is not present in the retrieved sources; inference relies on trial description rather than cited data."], "green": []}, "rationale": "The study employed a 3+3 dose\u2011escalation design and reported DLT occurrences (none at DL1, two at DL2), allowing determination of the MTD, which satisfies the primary objective of assessing DLT incidence in a phase\u202f1 trial.", "citations": [{"title": "Clinical Trial Design and Drug Approval in Oncology", "url": "https://doi.org/10.6004/jadpro.2020.11.7.7"}]}
{"abstract_id": 3719, "endpoint_id": 292, "truth": 1, "pred": 1, "blended_prob": 0.7070000000000001, "llm_prob": 0.72, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["small sample size (n=25 per arm) may limit robustness"], "green": ["p-value meets predefined significance threshold"]}, "rationale": "The randomized comparison reported a 15% vs 8% reduction in swallowing difficulties with a p\u2011value of 0.042, which is below the pre\u2011specified 0.05 significance level, indicating a statistically significant improvement for the metronomic therapy despite the modest sample size.", "citations": []}
{"abstract_id": 390, "endpoint_id": 28, "truth": 0, "pred": 1, "blended_prob": 0.8200000000000001, "llm_prob": 0.9, "base_prob": 0.7, "base_note": "Base rate from phase_2 / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["single-arm sequential cohorts; small sample size; non-randomized design"], "green": []}, "rationale": "The reported hazard ratio for PFS is 0.68 with a 95% CI of 0.37\u20111.24; the upper bound exceeds 1, so the superiority criterion (HR 95% CI upper bound <1) is not satisfied. Additionally, the study uses sequential, non\u2011randomized cohorts with only 50 patients, limiting robustness.", "citations": []}
{"abstract_id": 6067, "endpoint_id": 30, "truth": 1, "pred": 1, "blended_prob": 0.9139999999999999, "llm_prob": 0.94, "base_prob": 0.875, "base_note": "Base rate from phase_3_plus / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target tyrosine kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The randomized, double\u2011blind phase\u202f3 trial reported median PFS for patients with \u2264\u202f3 prior lines of 4.86\u202fmo (catequentinib) vs 1.41\u202fmo (placebo) with a p\u2011value\u202f=\u202f0.0046, satisfying the superiority criterion (p\u202f<\u202f0.05) despite the modest sample size.", "citations": [{"title": "Catequentinib phase\u202f3 trial in advanced/metastatic leiomyosarcoma (NCT03016819)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT03016819"}]}
{"abstract_id": 2329, "endpoint_id": 120, "truth": 0, "pred": 1, "blended_prob": 0.7861176470588235, "llm_prob": 0.82, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Small sample size and exploratory nature of the analysis limit confidence in the statistical result."], "green": []}, "rationale": "The exploratory subgroup analysis reported an ORR of 85.7% vs 55.6% with a p\u2011value of 0.308, which does not meet the predefined significance threshold (p\u202f<\u202f0.05). The study\u2019s single\u2011arm design, limited evaluable cohort (16 patients), and lack of a control group further reduce the robustness of this biomarker\u2011driven endpoint.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 390, "endpoint_id": 25, "truth": 0, "pred": 1, "blended_prob": 0.8320000000000001, "llm_prob": 0.92, "base_prob": 0.7, "base_note": "Base rate from phase_2 / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["non\u2011randomized sequential cohorts; small sample size; p\u2011value > 0.05"], "green": []}, "rationale": "The immunotherapy run\u2011in cohort had an ORR of 47% versus 23% in the chemotherapy run\u2011in cohort, but the reported p\u2011value was 0.08, which does not meet the predefined superiority threshold of p\u202f<\u202f0.05. The study is single\u2011arm with sequential cohorts, limiting the robustness of the comparison.", "citations": [{"title": "Trial abstract NCT02752685", "url": "http://www.clinicaltrials.gov/ct2/show/NCT02752685"}]}
{"abstract_id": 1633, "endpoint_id": 97, "truth": 1, "pred": 1, "blended_prob": 0.8134482758620689, "llm_prob": 0.85, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target erbb2/3 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Evidence for the actual number of patients achieving disease control is not present in the retrieved citations."], "green": []}, "rationale": "The trial used a Simon two\u2011stage design with a primary endpoint of disease control (CR, PR, or stable disease \u226516 weeks) in a bladder cancer cohort of 28 patients, requiring \u22657 responses to reject the null. The reported disease control rate of 37% exceeds this threshold, indicating the decision rule was met.", "citations": []}
{"abstract_id": 1469, "endpoint_id": 268, "truth": 1, "pred": 1, "blended_prob": 0.6319058823529412, "llm_prob": 0.68, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "yellow", "reason": "Target programmed cell death-1 (pd-1) not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size", "exploratory endpoint"], "green": []}, "rationale": "The trial reports a statistically significant decrease in macrophages at cycle 4 (p = 0.048), meeting the predefined p<0.05 decision rule. However, the finding is based on a small evaluable cohort (n=10) and is exploratory, warranting cautious interpretation.", "citations": []}
{"abstract_id": 6056, "endpoint_id": 32, "truth": 1, "pred": 1, "blended_prob": 0.6699999999999999, "llm_prob": 0.7, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target parp, cdk4/6 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size (n=12) limits robustness of safety conclusions"], "green": []}, "rationale": "In the dose-escalation cohort of 12 patients, only 25% experienced grade \u22653 treatment\u2011related adverse events and two dose\u2011limiting toxicities were observed, leading to the selection of a recommended phase 2 dose, indicating that safety and tolerability were adequately characterized to meet the endpoint.", "citations": []}
{"abstract_id": 48, "endpoint_id": 322, "truth": 1, "pred": 1, "blended_prob": 0.683, "llm_prob": 0.68, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Insufficient direct citation of trial DCR results; reliance on trial details rather than retrieved external evidence."], "green": []}, "rationale": "The trial reports disease control rates of 82.4% (Arm A) and 85.7% (Arm B) versus 61.8% for regorafenib (Arm C), with rate differences of 20.6% and 23.9% respectively and p-values \u22640.003, indicating superiority per the Cochran-Mantel-Haenszel test as stipulated in the decision rule.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 65, "endpoint_id": 155, "truth": 1, "pred": 1, "blended_prob": 0.5885714285714285, "llm_prob": 0.6, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target aromatase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Evidence for the specific DRFI result is not directly cited in the retrieved sources"], "green": []}, "rationale": "The combined TEXT+SOFT analysis reports a statistically significant improvement in DRFI for exemestane\u202f+\u202fOFS versus tamoxifen\u202f+\u202fOFS, meeting the superiority rule (p\u202f<\u202f0.05). However, the retrieved evidence does not include the trial-specific DRFI data, so confidence is moderated.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 4795, "endpoint_id": 296, "truth": 1, "pred": 1, "blended_prob": 0.8134482758620689, "llm_prob": 0.85, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target her2 protein not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size for interim decision"], "green": []}, "rationale": "The trial\u2019s primary endpoint is ORR, assessed after 9 evaluable patients. The interim rule requires \u22652 responses to continue. The reported data show 3 partial responses (33.3% ORR), satisfying the rule, so the study should proceed. While the sample is small, the predefined criterion is met.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 6196, "endpoint_id": 41, "truth": 1, "pred": 1, "blended_prob": 0.622, "llm_prob": 0.62, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient citation evidence for the reported p\u2011value on the secondary \u2018no emesis\u2019 endpoint"], "green": []}, "rationale": "The trial is a double\u2011blind, placebo\u2011controlled Phase III study with 148 patients receiving olanzapine and 153 receiving placebo, evaluating no emesis as a secondary endpoint. The reported results show a statistically significant reduction in vomiting (p\u202f<\u202f0.001), which meets the superiority criterion of p\u202f<\u202f0.05. However, the supporting data are not present in the retrieved external evidence, reducing confidence.", "citations": []}
{"abstract_id": 3905, "endpoint_id": 195, "truth": 1, "pred": 1, "blended_prob": 0.6950000000000001, "llm_prob": 0.7, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["small sample size (n=10)", "single\u2011arm design, limited evidence for DIC outcome"], "green": []}, "rationale": "The trial reports that none of the ten high\u2011risk APL patients experienced disseminated intravascular coagulation, meeting the decision rule of no DIC. However, the evidence is based on a very small, single\u2011arm cohort, limiting robustness.", "citations": []}
{"abstract_id": 2892, "endpoint_id": 127, "truth": 1, "pred": 1, "blended_prob": 0.7100000000000001, "llm_prob": 0.65, "base_prob": 0.8, "base_note": "Base rate from phase_3_plus / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Statistical significance of the ORR difference is not directly reported in the retrieved evidence; inference is based on overlapping confidence intervals in the ITT population and non\u2011overlapping intervals in the intermediate/poor\u2011risk subgroup."], "green": []}, "rationale": "The trial is a phase\u20113, randomized, 1:1 study with 1,096 patients comparing nivolumab\u202f+\u202fipilimumab to sunitinib. The primary endpoint (IRRC\u2011assessed ORR) was higher in the immunotherapy arm (42% vs 27% in the intermediate/poor\u2011risk group) and meets the superiority hypothesis, supported by the large sample size and robust independent radiology review.", "citations": [{"title": "iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics", "url": "https://recist.eortc.org/recist/wp-content/uploads/sites/4/2017/03/Manuscript_IRECIST_Lancet-Oncology_Seymour-et-al_revision_FINAL_clean_nov25.pdf"}]}
{"abstract_id": 1698, "endpoint_id": 101, "truth": 0, "pred": 1, "blended_prob": 0.879448275862069, "llm_prob": 0.96, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target fgfr1-3 tyrosine kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size (n=15) and wide confidence interval"], "green": []}, "rationale": "The primary endpoint for Group C required a one\u2011sided p\u2011value <0.05 to reject the null hypothesis of ORR \u22645%. The reported ORR by independent central review was 6.7% with a p\u2011value of 0.5367, far above the significance threshold, indicating the endpoint was not met.", "citations": [{"title": "Phase 2 basket trial of tasurgratinib in advanced solid tumors with FGFR alterations (NCT04962867)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04962867"}]}
{"abstract_id": 97, "endpoint_id": 16, "truth": 1, "pred": 1, "blended_prob": 0.9057777777777778, "llm_prob": 0.88, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target egfr and il13ra2 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size (n=18) typical for phase\u202f1 3+3 design may limit robustness"], "green": []}, "rationale": "The trial employed a standard 3+3 dose\u2011escalation design to assess dose\u2011limiting toxicity (DLT) as the primary endpoint, enrolling 6 patients per dose level (total 18). One DLT was observed at the highest dose, allowing determination of the maximum tolerated dose, which aligns with typical phase\u202f1 oncology methodology.", "citations": [{"title": "Clinical Trial Design and Drug Approval in Oncology", "url": "https://doi.org/10.6004/jadpro.2020.11.7.7"}]}
{"abstract_id": 48, "endpoint_id": 323, "truth": 1, "pred": 1, "blended_prob": 0.9135, "llm_prob": 0.96, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The trial reports objective response rates of 44.1% (Arm A) and 34.3% (Arm B) versus 2.9% (control) with statistically significant p\u2011values (0.003 and <0.001) derived from a Cochran\u2011Mantel\u2011Haenszel rate\u2011difference test, satisfying the predefined superiority criterion for the primary ORR endpoint.", "citations": [{"title": "LBA3516", "url": "http://www.clinicaltrials.gov/ct2/show/NCT06089330"}]}
{"abstract_id": 4540, "endpoint_id": 295, "truth": 1, "pred": 1, "blended_prob": 0.9135, "llm_prob": 0.96, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target alk or ros1 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "In Stage\u202f1, 8 patients were evaluable and 4 achieved major pathologic response (MPR), which exceeds the early\u2011stopping criterion of \u22641 MPR; therefore the study does not meet the condition to stop early.", "citations": [{"title": "Neo-INFINITY study (NCT05765877)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05765877"}]}
{"abstract_id": 65, "endpoint_id": 156, "truth": 1, "pred": 1, "blended_prob": 0.7385714285714285, "llm_prob": 0.85, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target aromatase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Evidence for statistical significance of BCFI is based on trial summary rather than a directly cited source"], "green": []}, "rationale": "The combined TEXT+SOFT analysis (n\u22484,690) directly compares E+OFS to T+OFS and reports a significant improvement in invasive breast cancer\u2011free interval, meeting the superiority criterion (p<0.05). The large sample size and long follow\u2011up (15\u201316.6 years) support robustness of the endpoint.", "citations": []}
{"abstract_id": 1118, "endpoint_id": 63, "truth": 1, "pred": 1, "blended_prob": 0.7575000000000001, "llm_prob": 0.7, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target ampk-foxo3 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Limited direct evidence for the reported 1\u2011year PFS rate; decision relies on trial summary rather than retrieved citations."], "green": []}, "rationale": "The single\u2011arm phase I/II study reports a 1\u2011year PFS of 47.6%, exceeding the predefined 27% threshold, indicating the primary endpoint was met; however, the retrieved literature does not contain the specific trial result, so confidence is moderated.", "citations": [{"title": "RECIST 1.1: Response Evaluation Criteria in Solid Tumors (Guidelines)", "url": "https://project.eortc.org/recist/wp-content/uploads/sites/4/2015/03/RECISTGuidelines.pdf"}]}
{"abstract_id": 41, "endpoint_id": 321, "truth": 0, "pred": 1, "blended_prob": 0.7197230769230769, "llm_prob": 0.82, "base_prob": 0.7692307692307693, "base_note": "Base rate from phase_2 / secondary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Primary analysis of 2nd PFS did not reach statistical significance (p=0.07)"], "green": []}, "rationale": "The randomized phase II trial compared panitumumab\u2192regorafenib versus regorafenib\u2192panitumumab in chemorefractory RAS/BRAF\u2011wt mCRC. For the secondary 2nd PFS endpoint, the primary analysis set showed a hazard ratio of 0.76 with a stratified log\u2011rank p\u2011value of 0.07, which does not meet the superiority threshold of p\u202f<\u202f0.05. Although the per\u2011protocol analysis yielded p\u202f=\u202f0.03, the decision rule is based on the primary analysis, so superiority is not demonstrated.", "citations": [{"title": "PARERE trial results \u2013 2nd PFS", "url": "https://clinicaltrials.gov/ct2/show/NCT04787341"}]}
{"abstract_id": 3924, "endpoint_id": 201, "truth": 1, "pred": 1, "blended_prob": 0.7977777777777777, "llm_prob": 0.7, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cd19 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Limited direct evidence linking DLT to regulatory guidance"], "green": []}, "rationale": "The trial is a phase\u20111 dose\u2011escalation study that uses accelerated titration and a 3+3 design to evaluate dose\u2011limiting toxicity and determine the maximum tolerated dose, which is the standard approach for primary safety endpoints in early\u2011phase oncology trials.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 1318, "endpoint_id": 81, "truth": 1, "pred": 1, "blended_prob": 0.7141176470588235, "llm_prob": 0.7, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient direct citation for the reported p\u2011value; endpoint significance inferred from provided abstract text not present in retrieved evidence."], "green": []}, "rationale": "The trial reports a p\u2011value of 0.025 for the increase in double positive T lymphocyte subset percent in the combination arm versus control, which meets the predefined significance threshold of p\u202f<\u202f0.05. The randomized design with 53 patients provides a modest sample, but the reported statistical test supports a positive finding for this exploratory endpoint.", "citations": []}
{"abstract_id": 1318, "endpoint_id": 77, "truth": 0, "pred": 1, "blended_prob": 0.6699999999999999, "llm_prob": 0.7, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for OS p\u2011value is only in trial description, not in retrieved citations"], "green": []}, "rationale": "The randomized study of 53 LACC patients reported no statistical difference in overall survival (p = 0.414), which exceeds the significance threshold of 0.05, indicating the OS endpoint is not met.", "citations": []}
{"abstract_id": 327, "endpoint_id": 20, "truth": 1, "pred": 1, "blended_prob": 0.7804347826086957, "llm_prob": 0.75, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Evidence for the OS difference is not directly cited from the retrieved external snippets"], "green": []}, "rationale": "The exploratory endpoint compares overall survival between high\u2011TIL and low\u2011TIL patients. The trial report states a significant OS advantage for high\u2011TIL patients (23.1 vs 10.3 months, P\u202f=\u202f0.003), which meets the superiority decision rule (p\u202f<\u202f0.05). The sample size (90 patients) is modest but sufficient for this exploratory analysis, and the p\u2011value indicates a robust finding despite the single\u2011arm design.", "citations": []}
{"abstract_id": 1058, "endpoint_id": 59, "truth": 0, "pred": 1, "blended_prob": 0.7834482758620689, "llm_prob": 0.8, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target fgfr1-3 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient direct citation for the observed ORR value; decision based on trial summary rather than retrieved evidence."], "green": []}, "rationale": "The trial reports an ORR of 8% in cohort A, which is well below the pre\u2011specified efficacy threshold of >28% for the primary endpoint, indicating the endpoint was not met despite the adequate sample size for a phase\u20112 single\u2011arm study.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 6196, "endpoint_id": 42, "truth": 1, "pred": 0, "blended_prob": 0.43, "llm_prob": 0.3, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient direct evidence for the rescue\u2011medication endpoint in the retrieved snippets"], "green": []}, "rationale": "The trial abstract states a p\u2011value of 0.008 for rescue therapy use, which would meet the superiority criterion, but none of the retrieved evidence excerpts contain this data; therefore we cannot confirm the endpoint result from the available sources.", "citations": []}
{"abstract_id": 1052, "endpoint_id": 55, "truth": 1, "pred": 1, "blended_prob": 0.785, "llm_prob": 0.85, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Citation does not directly contain the trial\u2019s hazard ratio data; evidence relies on trial description rather than retrieved sources."], "green": []}, "rationale": "The CATNON phase III trial randomized IDH\u2011mutant anaplastic glioma patients to adjuvant temozolomide versus radiotherapy alone and reported a hazard ratio for overall survival of 0.54 (95%\u202fCI\u202f0.42\u20110.69, p\u202f<\u202f0.0001), satisfying the superiority criteria of HR\u202f<\u202f1 with a confidence interval excluding 1 and p\u202f<\u202f0.05.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 1201, "endpoint_id": 70, "truth": 1, "pred": 1, "blended_prob": 0.7575000000000001, "llm_prob": 0.7, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["small sample size (n=6)", "limited external evidence"], "green": []}, "rationale": "The trial reports no dose\u2011limiting toxicities, neurotoxicity, CRS > Grade\u202f2, or GVHD, satisfying the predefined safety primary endpoint, but the conclusion is based on a very small cohort of six patients, limiting robustness.", "citations": []}
{"abstract_id": 3925, "endpoint_id": 210, "truth": 0, "pred": 1, "blended_prob": 0.647, "llm_prob": 0.62, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cyp3a not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient direct evidence linking the reported CRc rates to a statistically significant difference (p\u202f<\u202f0.05)"], "green": []}, "rationale": "The trial reports CRc rates of 60% vs 63.6% with a p\u2011value of 1.0, indicating no statistically significant difference; however, this specific data is not present in the retrieved evidence, reducing confidence in the assessment.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 1941, "endpoint_id": 112, "truth": 1, "pred": 1, "blended_prob": 0.839, "llm_prob": 0.94, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["small sample size per arm (\u224836\u201137 PP participants) may limit precision"], "green": ["p\u2011value < 0.05 demonstrates statistical superiority"]}, "rationale": "The per\u2011protocol analysis shows a pCR rate of 30.6% with mFOLFOXIRI+AK104 versus 10.8% with mFOLFOX6, and the reported two\u2011sided p\u2011value is 0.036, which meets the predefined superiority threshold (p\u202f<\u202f0.05). Although the PP cohort is modest in size, the result is statistically significant.", "citations": [{"title": "Pathologic outcome and surgical parameters (OPTICAL\u20112 trial)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05571644"}]}
{"abstract_id": 19, "endpoint_id": 346, "truth": 1, "pred": 1, "blended_prob": 0.7714482758620689, "llm_prob": 0.78, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["primary endpoint result not directly cited from retrieved evidence"], "green": []}, "rationale": "The randomized phase 2 trial enrolled 173 heavily pretreated R/M NPC patients and reported a statistically significant improvement in BICR-assessed PFS for MRG003 versus chemotherapy (HR\u202f=\u202f0.63, 95%\u202fCI\u202f0.43\u20130.91, P\u202f=\u202f0.0146), meeting both the p\u2011value and HR\u2011CI criteria for the primary endpoint.", "citations": []}
{"abstract_id": 65, "endpoint_id": 160, "truth": 0, "pred": 1, "blended_prob": 0.7865714285714286, "llm_prob": 0.93, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target aromatase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The trial reports a hazard ratio for overall survival of T+OFS vs T of 0.87 with a 95% CI of 0.68\u20111.10, which includes 1, indicating that superiority was not demonstrated according to the predefined decision rule.", "citations": [{"title": "Long-term follow-up of the SOFT and TEXT randomized trials", "url": "http://www.clinicaltrials.gov/ct2/show/NCT00066690"}]}
{"abstract_id": 390, "endpoint_id": 23, "truth": 1, "pred": 1, "blended_prob": 0.9004347826086956, "llm_prob": 0.95, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["Significant correlation (p=0.0075) reported for LNR with OS"]}, "rationale": "The single\u2011arm phase II study of pembrolizumab\u202f+\u202fnab\u2011paclitaxel in 50 mTNBC patients reported a statistically significant positive correlation between higher lymphocyte\u2011to\u2011neutrophil ratio and overall survival (R=0.37, p=0.0075), satisfying the predefined decision rule (p\u202f<\u202f0.05). The sample size and follow\u2011up are adequate for exploratory biomarker analysis.", "citations": [{"title": "NCT02752685 \u2013 Pembrolizumab plus nab\u2011paclitaxel in metastatic triple\u2011negative breast cancer", "url": "http://www.clinicaltrials.gov/ct2/show/NCT02752685"}]}
{"abstract_id": 19, "endpoint_id": 345, "truth": 1, "pred": 1, "blended_prob": 0.9064347826086956, "llm_prob": 0.96, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["HR confidence interval excludes 1 in the supplementary analysis"]}, "rationale": "The supplementary OS analysis reports a hazard ratio of 0.59 with a 95% CI of 0.37 to 0.93, which excludes 1, satisfying the predefined decision rule for statistical significance. The trial is a randomized phase 2 study with 173 patients, providing adequate sample size for this exploratory endpoint.", "citations": [{"title": "Abstract (HTML) \u2013 Becotatug vedotin (MRG003) vs chemotherapy in heavily pretreated R/M NPC", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05126719"}]}
{"abstract_id": 1274, "endpoint_id": 73, "truth": 1, "pred": 1, "blended_prob": 0.9075, "llm_prob": 0.95, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target axl, mer, csf1r not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The trial explicitly states that the Part 1 dose escalation using a mTPI design successfully identified and confirmed the Part 2 dose of Q702 at 120\u202fmg, satisfying the primary endpoint of dose determination.", "citations": [{"title": "QRNT-008 (NCT05438420) \u2013 Phase 1b/2 study of adrixetinib (Q702) plus pembrolizumab", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05438420"}]}
{"abstract_id": 6221, "endpoint_id": 43, "truth": 1, "pred": 1, "blended_prob": 0.6661176470588235, "llm_prob": 0.62, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for the p\u2011value comes from the trial description, not from the retrieved external snippets; confidence is limited."], "green": []}, "rationale": "The trial reports a predefined exploratory superiority analysis of the treatment\u2011success rate with a p\u2011value of 0.013, which meets the superiority criterion (p\u202f<\u202f0.05). However, this information is not present in the retrieved external evidence, reducing certainty.", "citations": []}
{"abstract_id": 17, "endpoint_id": 325, "truth": 1, "pred": 1, "blended_prob": 0.8780000000000001, "llm_prob": 0.93, "base_prob": 0.8, "base_note": "Base rate from phase_3_plus / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Citation support limited to trial summary; primary result not present in retrieved external sources."], "green": []}, "rationale": "The phase 3 trial reports a hazard ratio of 0.66 (95%\u202fCI\u202f0.49\u20110.89, p\u202f=\u202f0.005) for event\u2011free survival, exceeding the pre\u2011specified significance threshold, indicating a statistically significant improvement with PAXG versus mFOLFIRINOX. Sample size (260 patients, 173 events) provides 80% power as planned, supporting robustness of the finding.", "citations": []}
{"abstract_id": 3925, "endpoint_id": 205, "truth": 1, "pred": 1, "blended_prob": 0.7741176470588236, "llm_prob": 0.8, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cyp3a not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Small sample size (n=31) limits precision of the estimate"], "green": []}, "rationale": "The trial reports a p\u2011value of 0.569 for culture\u2011positive infections, which exceeds the 0.05 threshold, indicating no statistically significant difference in this exploratory safety endpoint between the VEN\u202f50\u202fmg\u202f+\u202fposaconazole and VEN\u202f400\u202fmg arms. However, the modest total enrollment (31 patients) reduces confidence in the estimate.", "citations": [{"title": "Trial abstract \u2013 Culture\u2011Positive Infections", "url": ""}]}
{"abstract_id": 4275, "endpoint_id": 220, "truth": 1, "pred": 1, "blended_prob": 0.723448275862069, "llm_prob": 0.7, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Primary endpoint result (MRD\u2011neg 73.2%) is taken from trial description; no directly retrieved external citation available"], "green": []}, "rationale": "The single\u2011arm phase\u202fII CONCEPT trial in high\u2011risk NDMM reported an MRD\u2011negativity rate of 73.2% after consolidation, which surpasses the null hypothesis threshold of \u226450%, indicating the primary endpoint was achieved despite the lack of external citation for the specific result.", "citations": []}
{"abstract_id": 1469, "endpoint_id": 263, "truth": 1, "pred": 1, "blended_prob": 0.6211058823529412, "llm_prob": 0.66, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "yellow", "reason": "Target programmed cell death-1 (pd-1) not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size (n=10 evaluable)", "exploratory endpoint"], "green": []}, "rationale": "The trial reports that at cycle 4 there were no changes in CD4 count, directly satisfying the decision rule of no significant CD4 change. However, the endpoint is exploratory and evaluated in only 10 patients, limiting statistical robustness.", "citations": [{"title": "Starkap (NCT05646082) abstract \u2013 CD4 count unchanged", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05646082"}]}
{"abstract_id": 3719, "endpoint_id": 289, "truth": 0, "pred": 1, "blended_prob": 0.647, "llm_prob": 0.62, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for the overall HRQoL comparison is not directly cited from the retrieved sources; inference is based on the abstract summary."], "green": []}, "rationale": "The trial randomized 50 tracheostomized H&N SCC patients to metronomic therapy versus cisplatin-based radiochemotherapy and assessed HRQoL using validated questionnaires. While several symptom domains showed statistically significant improvements (p\u202f<\u202f0.05), the authors explicitly state that overall HRQoL scores at study end were comparable between groups, indicating no significant difference for the primary overall HRQoL endpoint.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 73, "endpoint_id": 162, "truth": 1, "pred": 1, "blended_prob": 0.896, "llm_prob": 0.96, "base_prob": 0.8, "base_note": "Base rate from phase_3_plus / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The phase\u20113 randomized trial of 1,282 premenopausal HR\u2011positive women reported a hazard ratio for disease\u2011free survival of 0.68 with a 95\u202f% CI of 0.53\u20110.87; the upper bound is below 1.0, meeting the predefined superiority criterion.", "citations": [{"title": "ASTRRA trial \u2013 DFS results with tamoxifen\u202f+\u202fOFS vs tamoxifen alone", "url": "http://www.clinicaltrials.gov/ct2/show/NCT00912548"}]}
{"abstract_id": 2248, "endpoint_id": 113, "truth": 1, "pred": 1, "blended_prob": 0.812, "llm_prob": 0.82, "base_prob": 0.8, "base_note": "Base rate from phase_3_plus / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Small sample size (n=68) and early termination may limit robustness"], "green": []}, "rationale": "The phase III randomized trial met its primary endpoint of overall survival with a statistically significant hazard ratio (HR 0.46) and p\u2011value of 0.04, indicating superiority of neoadjuvant gemcitabine/cisplatin over direct surgery. However, the modest sample size and early stop due to slow enrollment warrant caution.", "citations": []}
{"abstract_id": 2892, "endpoint_id": 128, "truth": 1, "pred": 1, "blended_prob": 0.896, "llm_prob": 0.96, "base_prob": 0.8, "base_note": "Base rate from phase_3_plus / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": [], "green": ["large randomized phase\u20113 trial", "robust overall survival endpoint", "long median follow\u2011up (9\u202fyears)"]}, "rationale": "The phase\u20113 CheckMate\u202f214 trial randomized 1,096 patients with advanced clear\u2011cell RCC to nivolumab\u202f+\u202fipilimumab versus sunitinib. Overall survival hazard ratios were 0.71 in the intent\u2011to\u2011treat population and 0.69 in the intermediate/poor\u2011risk subgroup, both below 1, satisfying the inferred superiority hypothesis for OS.", "citations": []}
{"abstract_id": 5020, "endpoint_id": 251, "truth": 1, "pred": 1, "blended_prob": 0.8577777777777778, "llm_prob": 0.8, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target mbil15 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size (n=11) and lack of directly cited evidence"], "green": []}, "rationale": "The phase 1 single\u2011arm study reports no dose\u2011limiting toxicities among 11 patients (including 6 at the RP2D), satisfying the primary safety decision rule. Although the sample is limited, the absence of DLTs, ICU transfers, and treatment\u2011related mortality indicates the safety endpoint is met.", "citations": []}
{"abstract_id": 2882, "endpoint_id": 137, "truth": 1, "pred": 1, "blended_prob": 0.9064347826086956, "llm_prob": 0.96, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": [], "green": ["statistically significant p\u2011value reported"]}, "rationale": "The interim analysis reports that ypT0 responses differed by Genomic Subtyping Classifier groups (luminal 73% vs non\u2011luminal 25%) with a p\u2011value of 0.04, which meets the pre\u2011specified decision rule of p\u202f<\u202f0.05 despite the modest sample size (31 efficacy\u2011evaluable patients).", "citations": [{"title": "SURE-02 (NCT05535218) interim results", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05535218"}]}
{"abstract_id": 1088, "endpoint_id": 60, "truth": 1, "pred": 1, "blended_prob": 0.7377777777777778, "llm_prob": 0.6, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target b7h3 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Evidence for manufacturing feasibility not directly supported by retrieved citations"], "green": []}, "rationale": "The trial enrolled 11 patients, all of whom had B7H3-CART successfully manufactured, meeting the predefined feasibility decision rule despite the small sample size typical of phase 1 studies.", "citations": []}
{"abstract_id": 41, "endpoint_id": 320, "truth": 1, "pred": 1, "blended_prob": 0.7845230769230769, "llm_prob": 0.94, "base_prob": 0.7692307692307693, "base_note": "Base rate from phase_2 / secondary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Limited sample size for the 2nd ORR analysis (75 vs 70 patients)"], "green": ["Randomized phase II design", "Statistically significant p\u2011value (<0.01) for 2nd ORR"]}, "rationale": "The randomized phase II trial compared panitumumab versus regorafenib in chemorefractory RAS/BRAF\u2011wt mCRC. The 2nd objective response rate was 0% in the regorafenib arm and 17.4% in the panitumumab arm, with a reported p\u202f<\u202f0.01, satisfying the superiority hypothesis (p\u202f<\u202f0.01). Although the subgroup size is modest, the design and clear statistical significance support a positive outcome.", "citations": [{"title": "LBA3515 \u2013 PARERE trial results", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04787341"}]}
{"abstract_id": 1318, "endpoint_id": 80, "truth": 1, "pred": 1, "blended_prob": 0.647, "llm_prob": 0.62, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient citation evidence for the reported CR rates and p\u2011value; data come from trial description not from retrieved external sources."], "green": []}, "rationale": "The randomized trial of 53 LACC patients reports a complete response rate of 44.4% with CCRT+tislelizumab versus 19.2% with CCRT alone (p\u202f=\u202f0.035), meeting the predefined significance threshold (p\u202f<\u202f0.05). The sample size is modest but the difference is statistically significant, supporting a positive outcome for the CR endpoint.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 4719, "endpoint_id": 248, "truth": 0, "pred": 1, "blended_prob": 0.75, "llm_prob": 0.85, "base_prob": 0.6, "base_note": "Base rate from unknown / co-primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["lack of external citation for the 3\u2011year survival data"], "green": []}, "rationale": "The phase II randomized trial compared afatinib (n=47) and osimertinib (n=48) with a minimum 3\u2011year follow\u2011up. The reported 3\u2011year survival rates were 54.7% for afatinib and 57.5% for osimertinib, with a non\u2011significant hazard ratio for overall survival (HR\u202f=\u202f1.15, P\u202f=\u202f0.64), indicating no superiority of afatinib over osimertinib.", "citations": []}
{"abstract_id": 6202, "endpoint_id": 46, "truth": 1, "pred": 1, "blended_prob": 0.71, "llm_prob": 0.6, "base_prob": 0.875, "base_note": "Base rate from phase_3_plus / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target thrombopoietin receptor not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient cited evidence for the endpoint result; the trial data are not present in the retrieved snippets."], "green": []}, "rationale": "The phase 3 randomized trial reports a median platelet nadir of 87\u202f\u00d710\u2079/L for romiplostim versus 58\u202f\u00d710\u2079/L for placebo with a p\u2011value of 0.005, which meets the predefined superiority criterion (p\u202f<\u202f0.05). However, the retrieved evidence does not contain these specific data, reducing confidence in the assessment.", "citations": []}
{"abstract_id": 1052, "endpoint_id": 57, "truth": 1, "pred": 1, "blended_prob": 0.851, "llm_prob": 0.96, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": [], "green": ["Robust hazard ratio with CI excluding 1 and p<0.0001"]}, "rationale": "The phase III CATNON trial randomized 751 patients and reported a hazard ratio of 0.647 (95%\u202fCI\u202f0.541\u20110.773; p\u202f<\u202f0.0001) for overall survival with adjuvant temozolomide versus radiotherapy alone in the intent\u2011to\u2011treat population, satisfying the superiority criteria of HR\u202f<\u202f1, CI not crossing 1, and p\u202f<\u202f0.05.", "citations": [{"title": "CATNON trial final analysis (NCT00626990)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT00626990"}]}
{"abstract_id": 3925, "endpoint_id": 207, "truth": 0, "pred": 1, "blended_prob": 0.665, "llm_prob": 0.65, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cyp3a not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Evidence for the neutropenic phase duration statistic is only present in the trial abstract, not in the retrieved external sources; therefore confidence is limited."], "green": []}, "rationale": "The trial reports a median neutropenia recovery of 17.5 vs 24 days with a p\u2011value of 0.4, which does not meet the predefined significance threshold (p\u202f<\u202f0.05). The small sample size (n=31) further limits statistical power, reinforcing the lack of significance.", "citations": []}
{"abstract_id": 4275, "endpoint_id": 219, "truth": 1, "pred": 1, "blended_prob": 0.6604347826086957, "llm_prob": 0.55, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Decision rule outcome inferred from trial summary; no direct citation of HR and CI in retrieved evidence"], "green": []}, "rationale": "The trial reports a hazard ratio of 0.16 with a 95% CI of 0.08\u20130.32 for PFS benefit when patients reach and remain MRD\u2011negative, which excludes 1 and thus meets the superiority decision rule. However, the retrieved evidence does not contain the specific HR data, so confidence is moderated.", "citations": [{"title": "Cancer Drug Approval Endpoints \u2013 FDA Guidance", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 3679, "endpoint_id": 188, "truth": 1, "pred": 1, "blended_prob": 0.8716923076923077, "llm_prob": 0.94, "base_prob": 0.7692307692307693, "base_note": "Base rate from phase_2 / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": [], "green": ["statistically significant CR improvement (p=0.001) with adequate sample size"]}, "rationale": "The phase\u20112 randomized trial (n=150) compared toripalimab\u202f+\u202fIC versus IC alone in LANPC and reported a complete response rate of 36.0% versus 13.3% after neoadjuvant treatment, with a p\u2011value of 0.001, satisfying the pre\u2011specified superiority rule (p<0.05). The endpoint is a recognized efficacy measure evaluated by RECIST 1.1, and the sample size is sufficient for a secondary endpoint, indicating a robust finding.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 97, "endpoint_id": 15, "truth": 1, "pred": 1, "blended_prob": 0.7977777777777777, "llm_prob": 0.7, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target egfr and il13ra2 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient direct evidence from retrieved snippets confirming the observed DLT and MTD determination; inference based on trial description."], "green": []}, "rationale": "The trial used a standard 3+3 dose-escalation design with three dose levels and reported only one dose\u2011limiting toxicity at the highest dose, which satisfies typical criteria for defining the maximum tolerated dose, indicating the primary endpoint was met.", "citations": [{"title": "Clinical Trial Design and Drug Approval in Oncology", "url": "https://doi.org/10.6004/jadpro.2020.11.7.7"}]}
{"abstract_id": 1049, "endpoint_id": 262, "truth": 1, "pred": 1, "blended_prob": 0.6661176470588235, "llm_prob": 0.62, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Limited direct citation evidence for completion rates; feasibility assessment relies on trial summary rather than retrieved literature."], "green": []}, "rationale": "The trial reports high completion rates for questionnaires (85%) and cognitive assessments (97.9%), which meet the predefined feasibility criteria of high completion. Although the sample size is modest (54 enrolled, 51 active), the observed rates are comparable or superior to historic norms, supporting feasibility.", "citations": []}
{"abstract_id": 6196, "endpoint_id": 35, "truth": 0, "pred": 1, "blended_prob": 0.8270000000000001, "llm_prob": 0.92, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["No external citation for the reported QOL outcome; inference based solely on trial details"], "green": []}, "rationale": "The trial reports mean EORTC GHS QOL scores of 61.6\u202f\u00b1\u202f8.6 (placebo) vs 62.9\u202f\u00b1\u202f9.2 (olanzapine) with a p\u2011value of 0.235, which does not meet the superiority threshold of p\u202f<\u202f0.05. The sample size (n\u2248300) is adequate for detecting moderate differences, but the observed difference is not statistically significant.", "citations": []}
{"abstract_id": 327, "endpoint_id": 19, "truth": 1, "pred": 1, "blended_prob": 0.8824347826086958, "llm_prob": 0.92, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["Biomarker tier GREEN; significant p\u2011value reported"]}, "rationale": "The single\u2011arm phase\u202fII trial of camrelizumab\u202f+\u202fnab\u2011paclitaxel/cisplatin enrolled 90 mTNBC patients and performed exploratory RNA\u2011seq analyses. Activation of the MYC target pathway was significantly associated with shorter PFS (HR\u202f7.4, 95%\u202fCI\u202f1.9\u201128.2, p\u202f=\u202f0.004), meeting the superiority decision rule (p\u202f<\u202f0.05). The sample size and clear hazard ratio with confidence interval support a robust finding.", "citations": [{"title": "Camrelizumab plus AP as first-line treatment in metastatic triple\u2011negative breast cancer (NCT04537286)", "url": "https://clinicaltrials.gov/ct2/show/NCT04537286"}]}
{"abstract_id": 2120, "endpoint_id": 274, "truth": 1, "pred": 1, "blended_prob": 0.7204347826086956, "llm_prob": 0.65, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Limited direct evidence for ctDNA endpoint in retrieved sources"], "green": []}, "rationale": "The trial reports a statistically significant decrease in ctDNA mutation count (P\u202f<\u202f0.001) associated with therapeutic response, meeting the p\u202f<\u202f0.05 decision rule; however, the retrieved external evidence does not directly corroborate this finding, warranting caution.", "citations": []}
{"abstract_id": 5216, "endpoint_id": 2, "truth": 1, "pred": 1, "blended_prob": 0.8175, "llm_prob": 0.8, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target alk-fusion proteins not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Limited external citation; decision based on trial summary details only"], "green": []}, "rationale": "The trial reports only one dose\u2011limiting toxicity among 21 safety\u2011evaluable pediatric patients, indicating an acceptable safety profile to confirm the recommended phase 2 dose, satisfying the predefined decision rule.", "citations": []}
{"abstract_id": 65, "endpoint_id": 153, "truth": 1, "pred": 1, "blended_prob": 0.8, "llm_prob": 0.8, "base_prob": 0.8, "base_note": "Base rate from phase_3_plus / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target aromatase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient direct citation for the reported hazard ratio; endpoint result inferred from trial summary rather than retrieved external sources."], "green": []}, "rationale": "The combined TEXT+SOFT analysis reports a 15\u2011year DFS hazard ratio of 0.82 (95%\u202fCI\u202f0.73\u20110.92) for exemestane\u202f+\u202fOFS versus tamoxifen\u202f+\u202fOFS, meeting the superiority rule that the CI excludes 1. The large sample (\u22484,690 patients) and long follow\u2011up support robustness of the finding.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 2892, "endpoint_id": 129, "truth": 1, "pred": 1, "blended_prob": 0.7985714285714285, "llm_prob": 0.95, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The trial reports a hazard ratio of 0.71 for overall survival in the intent\u2011to\u2011treat population, indicating a clear survival benefit (HR\u202f<\u202f1) for nivolumab\u202f+\u202fipilimumab versus sunitinib. The large sample size (n=1096) and long median follow\u2011up (9\u202fyears) provide robust evidence supporting the inferred superiority hypothesis.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 4860, "endpoint_id": 304, "truth": 0, "pred": 1, "blended_prob": 0.802, "llm_prob": 0.92, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target gut microflora and metabolites not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Limited sample size for secondary endpoint; p\u2011value > 0.05"], "green": []}, "rationale": "The randomized phase trial compared ICI\u202f+\u202fchemo with and without GQT in 94 patients (response\u2011evaluable n=45 vs n=43). The secondary ORR was 48.9% vs 36.2% with a reported p\u2011value of 0.211, which does not meet the pre\u2011specified significance threshold (p\u202f<\u202f0.05). Thus the endpoint is not statistically significant despite a numerically higher response rate in the GQT arm.", "citations": [{"title": "Trial abstract (ChiCTR2200062607) \u2013 ORR results", "url": "N/A"}]}
{"abstract_id": 2641, "endpoint_id": 281, "truth": 1, "pred": 1, "blended_prob": 0.8475, "llm_prob": 0.85, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for statistical significance is only reported in trial details, not in the retrieved external sources."], "green": []}, "rationale": "The study reports median recurrence\u2011free survival of 27.5\u202fmonths vs 16.2\u202fmonths with a p\u2011value of 0.04 and HR\u202f0.51, meeting the p\u202f<\u202f0.05 criterion for the primary endpoint despite a modest sample size (74 patients) and non\u2011randomized design.", "citations": []}
{"abstract_id": 209, "endpoint_id": 259, "truth": 1, "pred": 1, "blended_prob": 0.7977777777777777, "llm_prob": 0.7, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cyclin dependent kinase 4/6, poly-adp-ribose polymerase (parp) not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Limited direct citation of trial-specific MTD determination; reliance on generic trial design sources."], "green": []}, "rationale": "The study employed a traditional 3+3 dose\u2011escalation algorithm, reported dose\u2011limiting toxicities at the higher dose level, and identified the lower dose level as the maximum\u2011tolerated dose, satisfying the primary endpoint definition. However, the retrieved evidence does not contain the trial\u2011specific data, only generic references to dose\u2011escalation designs, reducing confidence.", "citations": [{"title": "Clinical Trial Design and Drug Approval in Oncology", "url": "https://doi.org/10.6004/jadpro.2020.11.7.7"}]}
{"abstract_id": 3065, "endpoint_id": 148, "truth": 1, "pred": 1, "blended_prob": 0.8134482758620689, "llm_prob": 0.85, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Evidence for the p\u2011value comes from trial details, not from the retrieved external sources; external citations do not directly confirm the statistical result."], "green": []}, "rationale": "The randomized phase\u20112 trial reported median PFS of 3.4\u202fmonths with niraparib alone versus 5.6\u202fmonths with niraparib\u202f+\u202fcetrelimab, with a reported p\u2011value of 0.01, which meets the pre\u2011specified significance threshold (p\u202f<\u202f0.05) for the primary endpoint.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 1318, "endpoint_id": 83, "truth": 1, "pred": 1, "blended_prob": 0.6699999999999999, "llm_prob": 0.7, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["No direct citation for the toxicity result; inference based on trial description"], "green": []}, "rationale": "The trial reports no significant difference in acute adverse reactions (P > 0.05), satisfying the decision rule for the toxicity secondary endpoint, though the supporting evidence is not present in the retrieved external snippets.", "citations": []}
{"abstract_id": 6221, "endpoint_id": 45, "truth": 0, "pred": 1, "blended_prob": 0.9135, "llm_prob": 0.96, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": [], "green": ["robust randomized design with adequate sample size"]}, "rationale": "The randomized trial enrolled 105 patients (51 in the 3\u2011week arm, 54 in the 6\u2011week arm) and assessed treatment success at 8 weeks. The success rates were 66.7% vs 85.2%, giving a difference of \u201318.5% (80% CI \u201329.0 to \u20137.9), which exceeds the pre\u2011specified non\u2011inferiority margin of 16 percentage points; therefore non\u2011inferiority was not met.", "citations": []}
{"abstract_id": 1698, "endpoint_id": 99, "truth": 0, "pred": 1, "blended_prob": 0.855448275862069, "llm_prob": 0.92, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target fgfr1-3 tyrosine kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The primary endpoint requires a one\u2011sided p\u2011value <\u202f0.05 for ORR >\u202f5% in Group A. The reported ORR by independent central review is 20.0% with p\u202f=\u202f0.0861, which exceeds the significance threshold, indicating the endpoint was not met.", "citations": [{"title": "Tasurgratinib phase 2 basket trial (NCT04962867) \u2013 Objective response rate by ICR in Group A", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04962867"}]}
{"abstract_id": 5217, "endpoint_id": 11, "truth": 1, "pred": 1, "blended_prob": 0.7095, "llm_prob": 0.62, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["No direct citation from retrieved evidence supporting the RP2D determination; inference based on trial details provided."], "green": []}, "rationale": "The trial employed a rolling six design across four dose levels with 22 evaluable patients; only one DLT occurred at the highest dose (50\u202fmg/m\u00b2), leading investigators to declare 50\u202fmg/m\u00b2/day as the RP2D, satisfying the predefined safety-based decision rule.", "citations": []}
{"abstract_id": 4719, "endpoint_id": 241, "truth": 1, "pred": 1, "blended_prob": 0.6841176470588235, "llm_prob": 0.65, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Insufficient citation for OS result"], "green": []}, "rationale": "The phase II randomized trial reports that in patients with high Th2 (\u22657.20%) the OS hazard ratio for osimertinib versus afatinib was 2.77 with a p\u2011value of 0.03, which satisfies the predefined significance threshold (p\u202f<\u202f0.05). However, the supporting data are only present in the trial description and not in the retrieved external evidence, reducing confidence.", "citations": []}
{"abstract_id": 6196, "endpoint_id": 36, "truth": 1, "pred": 0, "blended_prob": 0.467, "llm_prob": 0.32, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient direct evidence of between-group p\u2011value for mean anxiety score"], "green": []}, "rationale": "The abstract reports significant within\u2011group changes in anxiety scores (p<0.001) for both placebo and olanzapine arms, but does not provide a direct between\u2011group comparison p\u2011value. Without explicit evidence that the between\u2011group difference meets the p<0.05 superiority criterion, the decision rule cannot be confirmed.", "citations": []}
{"abstract_id": 1469, "endpoint_id": 266, "truth": 0, "pred": 1, "blended_prob": 0.7615058823529413, "llm_prob": 0.92, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "yellow", "reason": "Target programmed cell death-1 (pd-1) not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["exploratory endpoint", "small sample size (n=10 evaluable)"], "green": []}, "rationale": "The trial reports a non\u2011significant rise in NK, CD4, and CD8 na\u00efve cells, indicating the p\u2011value did not meet the <0.05 threshold. With only 10 evaluable patients and an exploratory endpoint, the evidence is insufficient to claim statistical significance.", "citations": [{"title": "Starkap (NCT05646082) \u2013 Results", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05646082"}]}
{"abstract_id": 1372, "endpoint_id": 256, "truth": 1, "pred": 1, "blended_prob": 0.635, "llm_prob": 0.6, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target ctla-4 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Insufficient direct citation for DLT outcome; inference based on trial description not present in retrieved evidence."], "green": []}, "rationale": "The trial description states that the first three dose cohorts were completed and no dose\u2011limiting toxicities were reported, satisfying the decision rule of absence of DLTs. However, the retrieved evidence does not contain a direct citation confirming this outcome, reducing confidence.", "citations": []}
{"abstract_id": 2329, "endpoint_id": 121, "truth": 0, "pred": 1, "blended_prob": 0.8461176470588236, "llm_prob": 0.92, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["small sample size and exploratory single\u2011arm design limit statistical power"], "green": []}, "rationale": "The exploratory analysis comparing overall survival between DDR\u2011mutated (n=7) and non\u2011mutated patients reported a log\u2011rank P value of 0.116, which does not meet the pre\u2011specified significance threshold of p\u202f<\u202f0.05. The single\u2011arm design and limited number of evaluable patients further reduce the ability to detect a statistically significant difference.", "citations": [{"title": "Phase 1b/2 trial of surufatinib\u202f+\u202fKN046\u202f+\u202fGnP in first\u2011line advanced pancreatic cancer (NCT05832892)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05832892"}]}
{"abstract_id": 2744, "endpoint_id": 283, "truth": 1, "pred": 1, "blended_prob": 0.8475, "llm_prob": 0.85, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target pauf not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size (n=6) limits robustness of safety conclusion"], "green": []}, "rationale": "The trial reports no dose\u2011limiting toxicities during the 28\u2011day observation window in both dose cohorts, satisfying the primary safety endpoint. However, the very small cohort (6 patients) reduces confidence in the generalizability of this finding.", "citations": []}
{"abstract_id": 3719, "endpoint_id": 290, "truth": 1, "pred": 1, "blended_prob": 0.755, "llm_prob": 0.8, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["small sample size (n=25 per arm) may limit robustness"], "green": []}, "rationale": "The trial reports a statistically significant reduction in pain scores for the metronomic therapy group versus cisplatin (p = 0.031), meeting the predefined p\u2011value threshold. While the result is promising, the modest sample size warrants caution regarding the precision of the estimate.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 3925, "endpoint_id": 203, "truth": 1, "pred": 1, "blended_prob": 0.6661176470588235, "llm_prob": 0.62, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cyp3a not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient direct citation for the reported p\u2011value; reliance on trial summary rather than retrieved external sources."], "green": []}, "rationale": "The exploratory endpoint C0 shows a reported median difference with a p\u2011value of 0.004, which meets the <0.05 significance criterion. However, the supporting evidence is limited to the trial summary without external validation, reducing confidence.", "citations": []}
{"abstract_id": 1598, "endpoint_id": 92, "truth": 1, "pred": 1, "blended_prob": 0.6841176470588235, "llm_prob": 0.65, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target msln not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Limited sample size and only a single biopsy detection reported; endpoint evidence is sparse"], "green": []}, "rationale": "The trial reports that A2B694 was detected in an abdominal tumor biopsy of one pancreatic cancer patient 42 days after infusion, satisfying the decision rule of tumor infiltration detection, albeit in a very small cohort (n=5).", "citations": []}
{"abstract_id": 41, "endpoint_id": 318, "truth": 0, "pred": 1, "blended_prob": 0.6483913043478261, "llm_prob": 0.65, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["small per\u2011protocol sample size (n\u224868/69) and confidence interval crossing 1.0"], "green": []}, "rationale": "The per\u2011protocol analysis of 2nd PFS shows a median of 2.7\u202fmo vs 3.9\u202fmo (HR\u202f0.71, 95%\u202fCI\u202f0.5\u20131.01) with a stratified log\u2011rank p\u2011value of 0.03, which meets the p\u202f<\u202f0.05 superiority criterion, though the effect is borderline and based on a modest sample.", "citations": [{"title": "PARERE trial abstract (LBA3515) \u2013 2nd PFS per protocol population", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04787341"}]}
{"abstract_id": 5327, "endpoint_id": 305, "truth": 0, "pred": 1, "blended_prob": 0.7443000000000001, "llm_prob": 0.92, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "yellow", "reason": "Target gd2 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small_sample_size", "single_arm_design", "borderline_p_value"], "green": []}, "rationale": "The trial reports a 12\u2011month PFS of 76.9% with sintilimab vs 44.2% without (P\u202f=\u202f0.059), which does not meet the pre\u2011specified significance threshold of p\u202f<\u202f0.05. The analysis is based on a very small, non\u2011randomized cohort, limiting statistical power.", "citations": [{"title": "e22014 \u2013 NCT06013618", "url": "http://www.clinicaltrials.gov/ct2/show/NCT06013618"}]}
{"abstract_id": 3668, "endpoint_id": 186, "truth": 1, "pred": 1, "blended_prob": 0.6975, "llm_prob": 0.6, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Limited direct citation of trial outcome; OS result inferred from trial description rather than retrieved literature."], "green": []}, "rationale": "The single\u2011arm phase II study reports a 2\u2011year overall survival of 67.2% for the whole cohort and a statistically significant difference between re\u2011irradiation (73.8%) and no re\u2011irradiation (51.2%) groups (P\u202f=\u202f0.019), meeting the predefined p\u202f<\u202f0.05 criterion for the primary endpoint despite modest sample size.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 6196, "endpoint_id": 38, "truth": 1, "pred": 1, "blended_prob": 0.785, "llm_prob": 0.85, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for the sleep endpoint is only from trial details, not from external retrieved sources."], "green": []}, "rationale": "The randomized, placebo\u2011controlled Phase III trial reported a statistically significant increase in sleep hours/day for olanzapine (8.4\u202f\u00b1\u202f1.7\u202fh) versus placebo (5.29\u202f\u00b1\u202f1.13\u202fh) with p\u202f<\u202f0.001, meeting the superiority criterion of p\u202f<\u202f0.05 despite the modest sample size.", "citations": []}
{"abstract_id": 1598, "endpoint_id": 91, "truth": 1, "pred": 1, "blended_prob": 0.8475, "llm_prob": 0.85, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target msln not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Primary endpoint outcome not directly supported by retrieved external evidence"], "green": []}, "rationale": "The trial reports no dose\u2011limiting toxicities among the five participants, satisfying the predefined decision rule for the primary safety and tolerability endpoint. Although the sample size is very small, the absence of DLTs across all dose levels evaluated supports a positive safety assessment.", "citations": []}
{"abstract_id": 15, "endpoint_id": 334, "truth": 0, "pred": 1, "blended_prob": 0.8045714285714285, "llm_prob": 0.96, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["small sample size"], "green": ["randomized controlled design"]}, "rationale": "The phase\u20113 RCT of 49 patients reported median OS of 21.6 vs 37.2 months with a p\u2011value of 0.530, which fails the pre\u2011specified p\u202f<\u202f0.05 threshold. While the trial is appropriately randomized, the very limited sample size reduces statistical power to detect a survival difference.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 1222, "endpoint_id": 67, "truth": 1, "pred": 1, "blended_prob": 0.6748, "llm_prob": 0.62, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "yellow", "reason": "Target ccr8 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["limited_citation_evidence"], "green": []}, "rationale": "The phase\u20111 single\u2011arm study treated 13 R/R CTCL patients with ICP\u2011B05 across four dose levels. TEAEs occurred in 92.3% of patients, with grade\u202f\u22653 events in 46.2% and serious TEAEs in 16.7%, none fatal and only one deemed unrelated. The authors conclude the agent is safe and well tolerated, supporting a positive safety assessment despite the small sample size.", "citations": []}
{"abstract_id": 3905, "endpoint_id": 197, "truth": 1, "pred": 1, "blended_prob": 0.683, "llm_prob": 0.68, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Outcome not directly supported by retrieved external evidence; reliance on trial description"], "green": []}, "rationale": "The single\u2011arm study enrolled ten high\u2011risk APL patients unsuitable for anthracyclines and reported that all achieved complete hematological remission within 31 days of induction, satisfying the decision rule despite the small sample size and lack of a comparator.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 6067, "endpoint_id": 31, "truth": 1, "pred": 1, "blended_prob": 0.6920000000000001, "llm_prob": 0.62, "base_prob": 0.8, "base_note": "Base rate from phase_3_plus / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target tyrosine kinase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Limited direct evidence for the trial\u2019s p\u2011value and HR; inference based on trial description rather than retrieved citations."], "green": []}, "rationale": "The trial is a phase\u202f3, double\u2011blind, randomized 2:1 design with 110 evaluable patients, using blinded independent central review of PFS as the primary endpoint and a Log\u2011Rank test. The reported p\u2011value (0.0265) is below the 0.05 superiority threshold, indicating the endpoint is met, though the supporting data are not present in the retrieved literature, reducing confidence.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 4719, "endpoint_id": 246, "truth": 0, "pred": 1, "blended_prob": 0.851, "llm_prob": 0.96, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The trial reports median PFS of 16.7\u202fmo vs 14.5\u202fmo (HR\u202f1.17, 95%\u202fCI\u202f0.72\u20111.90) with a P\u2011value of 0.52, which does not meet the pre\u2011specified significance threshold of p\u202f<\u202f0.05. The sample size (\u224895 patients) is modest but sufficient to estimate the hazard ratio; however, the lack of statistical significance indicates the endpoint is not met.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 4112, "endpoint_id": 217, "truth": 1, "pred": 1, "blended_prob": 0.7237058823529413, "llm_prob": 0.85, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "yellow", "reason": "Target cd20, cd47 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["single_arm_design", "small_sample_size"], "green": []}, "rationale": "The trial reports no significant differences in ADA incidence rate between amulirafusp alfa monotherapy and the combination with lenalidomide, directly satisfying the decision rule despite the single\u2011arm design and limited sample (n=34, efficacy\u2011evaluable n=22).", "citations": [{"title": "Phase II study of amulirafusp alfa in relapsed/refractory follicular lymphoma (NCT05771883)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05771883"}]}
{"abstract_id": 3925, "endpoint_id": 211, "truth": 0, "pred": 1, "blended_prob": 0.8270000000000001, "llm_prob": 0.92, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cyp3a not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size; endpoint not statistically significant"], "green": []}, "rationale": "The MRD negativity rates were 30% vs 36.3% with a reported p\u2011value of 0.98, far above the 0.05 threshold, indicating no statistically significant difference despite the small cohort (n=31).", "citations": []}
{"abstract_id": 3632, "endpoint_id": 178, "truth": 1, "pred": 0, "blended_prob": 0.48344827586206895, "llm_prob": 0.3, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target braf v600e not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient retrieved evidence to confirm the reported R0/R1 resection rate"], "green": []}, "rationale": "The trial abstract reports a 97% R0/R1 resection rate, far exceeding the historical 5% benchmark, but this specific data is not present in the retrieved evidence snippets. Without citation from the provided sources, we cannot verify the improvement, leading to a cautious 'no' prediction with low confidence.", "citations": []}
{"abstract_id": 1469, "endpoint_id": 264, "truth": 1, "pred": 1, "blended_prob": 0.7237058823529413, "llm_prob": 0.85, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "yellow", "reason": "Target programmed cell death-1 (pd-1) not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size (n=10 evaluable)", "exploratory endpoint"], "green": []}, "rationale": "The trial reports a statistically significant decline in HHV-8 DNA at cycle 4 (p = 0.035), meeting the pre\u2011specified decision rule of p < 0.05. Although the sample is limited to 10 evaluable patients and the endpoint is exploratory, the observed p\u2011value satisfies the significance criterion.", "citations": [{"title": "Starkap (NCT05646082) abstract", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05646082"}]}
{"abstract_id": 2329, "endpoint_id": 123, "truth": 1, "pred": 1, "blended_prob": 0.7095, "llm_prob": 0.62, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Insufficient direct evidence from retrieved sources to confirm DLT outcomes"], "green": []}, "rationale": "The trial description states that no dose\u2011limiting toxicities occurred among the nine phase\u20111b patients, leading to selection of the 250\u202fmg dose as RP2D, which satisfies the primary DLT endpoint. However, the retrieved evidence does not contain the specific trial data, so confidence is moderated.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 450, "endpoint_id": 261, "truth": 1, "pred": 1, "blended_prob": 0.8277777777777777, "llm_prob": 0.75, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["small sample size (n=13) limits robustness of safety conclusions"], "green": []}, "rationale": "The phase I single\u2011arm trial of cemiplimab plus capecitabine reported no unexpected adverse events or dose\u2011limiting toxicities, indicating an acceptable safety profile, but the limited cohort of 13 patients warrants cautious interpretation.", "citations": []}
{"abstract_id": 327, "endpoint_id": 18, "truth": 1, "pred": 1, "blended_prob": 0.7024347826086956, "llm_prob": 0.62, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Evidence for KRAS association not present in retrieved citations"], "green": []}, "rationale": "The phase\u20112 single\u2011arm study of camrelizumab plus nab\u2011paclitaxel/cisplatin reported a hazard ratio of 3.2 (95%\u202fCI\u202f1.1\u20119.7, P\u202f=\u202f0.035) linking KRAS signaling activation to poorer overall survival, meeting the p\u202f<\u202f0.05 superiority criterion, but the retrieved evidence does not contain the specific citation.", "citations": []}
{"abstract_id": 327, "endpoint_id": 21, "truth": 1, "pred": 1, "blended_prob": 0.8824347826086958, "llm_prob": 0.92, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The exploratory OS analysis compared patients with irAEs to those without and reported a statistically significant longer median OS (29.3 vs 22.1 months) with a p\u2011value of 0.018, satisfying the superiority decision rule (p\u202f<\u202f0.05) in this phase\u20112 single\u2011arm study of 90 mTNBC patients.", "citations": [{"title": "Camrelizumab plus nab\u2011paclitaxel/cisplatin in first\u2011line metastatic triple\u2011negative breast cancer (NCT04537286)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04537286"}]}
{"abstract_id": 7, "endpoint_id": 328, "truth": 0, "pred": 0, "blended_prob": 0.31857142857142856, "llm_prob": 0.15, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target poly (adp-ribose) polymerase (parp)-1/2 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["OS analysis is interim and did not reach statistical significance (p=0.10)"], "green": []}, "rationale": "The phase\u20113 AMPLITUDE trial randomized 696 HRR\u2011altered mCSPC patients to NIRA\u202f+\u202fAAP vs AAP alone and reported an interim overall survival analysis with HR\u202f0.79 (95%\u202fCI\u202f0.59\u20111.04) and p\u202f=\u202f0.10, which does not satisfy the predefined superiority threshold of p\u202f<\u202f0.05.", "citations": [{"title": "AMPLITUDE trial (NCT04497844) abstract \u2013 OS interim analysis", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 2882, "endpoint_id": 135, "truth": 1, "pred": 1, "blended_prob": 0.7624347826086957, "llm_prob": 0.72, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["No directly retrieved source confirming the reported p\u2011value for stromal signature; inference based on trial abstract details."], "green": []}, "rationale": "The trial reports a statistically significant association between higher stromal signature and non\u2011ypT0 response (p = 0.004), which meets the predefined significance threshold (p < 0.05). Despite the small sample (31 efficacy\u2011evaluable patients), the finding is directly stated, supporting a positive prediction, though the lack of external citation reduces confidence.", "citations": []}
{"abstract_id": 2943, "endpoint_id": 142, "truth": 1, "pred": 1, "blended_prob": 0.735448275862069, "llm_prob": 0.72, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Limited direct citation for the observed 68% CRR; endpoint result comes from trial summary rather than retrieved literature."], "green": []}, "rationale": "The single\u2011arm phase\u202fII study reported a 3\u2011month complete response rate of 68% (17/25 evaluable patients), exceeding the pre\u2011specified target of 53% based on a pembrolizumab historical control of 41%, thus meeting its primary endpoint despite the modest sample size.", "citations": [{"title": "iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics", "url": "https://recist.eortc.org/recist/wp-content/uploads/sites/4/2017/03/Manuscript_IRECIST_Lancet-Oncology_Seymour-et-al_revision_FINAL_clean_nov25.pdf"}]}
{"abstract_id": 4727, "endpoint_id": 240, "truth": 1, "pred": 1, "blended_prob": 0.7024347826086956, "llm_prob": 0.62, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Insufficient external citation for the reported p\u2011value; reliance on trial abstract alone"], "green": []}, "rationale": "The exploratory endpoint reports a statistically significant association between post\u2011treatment ctDNA clearance and longer PFS (P\u202f=\u202f0.015), which satisfies the pre\u2011specified decision rule of p\u202f<\u202f0.05. However, the supporting evidence is limited to the trial\u2019s own data without independent corroboration, and the sample size for the ctDNA analysis is small (n\u202f=\u202f11), warranting caution.", "citations": []}
{"abstract_id": 2877, "endpoint_id": 130, "truth": 1, "pred": 1, "blended_prob": 0.896, "llm_prob": 0.96, "base_prob": 0.8, "base_note": "Base rate from phase_3_plus / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The phase\u20113, double\u2011blind, placebo\u2011controlled KEYNOTE\u2011564 trial randomized 994 patients (496 pembrolizumab, 498 placebo) and reported a disease\u2011free survival hazard ratio of 0.71 with a 95\u202f% CI of 0.59\u20130.86. The upper bound of the confidence interval is well below 1.0, satisfying the predefined superiority criterion for the primary DFS endpoint.", "citations": [{"title": "KEYNOTE-564 (NCT03142334) \u2013 Disease\u2011Free Survival Results", "url": "http://www.clinicaltrials.gov/ct2/show/NCT03142334"}]}
{"abstract_id": 3719, "endpoint_id": 291, "truth": 1, "pred": 1, "blended_prob": 0.803, "llm_prob": 0.88, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Small sample size (n=25 per arm) may limit robustness of the significance claim."], "green": []}, "rationale": "The randomized comparison reported a p\u2011value of 0.049 for improvement in speech-related challenges, which meets the predefined significance threshold (p<0.05). Despite the statistically significant result, the modest cohort size warrants caution regarding the precision of the estimate.", "citations": []}
{"abstract_id": 1318, "endpoint_id": 78, "truth": 0, "pred": 1, "blended_prob": 0.826, "llm_prob": 0.96, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient direct citation for PFS p\u2011value; inference based on provided trial summary not present in retrieved evidence."], "green": []}, "rationale": "The trial reports a PFS p\u2011value of 0.716, which exceeds the 0.05 threshold for statistical significance, indicating the secondary endpoint of PFS is not met despite the randomized design; however, the small sample size (53 patients) limits robustness.", "citations": []}
{"abstract_id": 48, "endpoint_id": 324, "truth": 1, "pred": 1, "blended_prob": 0.845, "llm_prob": 0.95, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["clear statistical significance"]}, "rationale": "The randomized phase II trial reports median PFS of 5.7\u202fmo (Arm\u202fA) and 7.4\u202fmo (Arm\u202fB) versus 2.9\u202fmo (regorafenib control) with p\u2011values of 0.003 and <0.001 respectively, meeting the pre\u2011specified superiority criterion (p\u202f<\u202f0.05). Sample sizes (\u224835 per arm) are adequate for a phase II comparison, and the stratified log\u2011rank test provides robust evidence of benefit.", "citations": [{"title": "LBA3516 \u2013 JMT101 + irinotecan \u00b1 SG001 vs regorafenib in mCRC", "url": "http://www.clinicaltrials.gov/ct2/show/NCT06089330"}]}
{"abstract_id": 5216, "endpoint_id": 1, "truth": 1, "pred": 1, "blended_prob": 0.6699999999999999, "llm_prob": 0.7, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target alk-fusion proteins not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Unclear pre\u2011specified response rate threshold; decision rule not explicitly stated in the provided data."], "green": []}, "rationale": "The single\u2011arm phase I/II trial reported a Best Overall Response rate of 87.5% (14/16 patients) among efficacy\u2011evaluable participants, indicating a high proportion of partial responses, which likely satisfies a typical pre\u2011specified efficacy threshold despite the exact target not being disclosed.", "citations": [{"title": "iMATRIX Alectinib phase I\u2011II study (NCT04774718) \u2013 Best Overall Response", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04774718"}]}
{"abstract_id": 46, "endpoint_id": 310, "truth": 1, "pred": 1, "blended_prob": 0.8836923076923077, "llm_prob": 0.96, "base_prob": 0.7692307692307693, "base_note": "Base rate from phase_2 / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target tumor angiogenesis and proliferation not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The randomized phase\u202fII trial reports an IRC\u2011assessed ORR of 16.88% with anlotinib versus 5.26% with placebo (p\u202f=\u202f0.0220), which meets the predefined significance threshold of p\u202f<\u202f0.05 for this secondary endpoint.", "citations": [{"title": "NCT04959500 \u2013 Anlotinib plus STUPP versus placebo plus STUPP in newly diagnosed glioblastoma", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04959500"}]}
{"abstract_id": 1274, "endpoint_id": 75, "truth": 1, "pred": 1, "blended_prob": 0.725, "llm_prob": 0.75, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target axl, mer, csf1r not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size (n=29) and single\u2011arm design limit robustness of safety conclusions"], "green": []}, "rationale": "The phase 1b single\u2011arm study of Q702\u202f+\u202fpembrolizumab reported no treatment\u2011related discontinuations, only one dose\u2011limiting toxicity, and the most common adverse events were laboratory abnormalities, indicating a manageable safety profile, though the limited sample size warrants caution.", "citations": [{"title": "QRNT-008 (NCT05438420) safety data", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05438420"}]}
{"abstract_id": 19, "endpoint_id": 343, "truth": 1, "pred": 1, "blended_prob": 0.885448275862069, "llm_prob": 0.97, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["Robust randomized design with adequate sample size and statistically significant ORR difference (p=0.0025)"]}, "rationale": "The phase 2 randomized trial enrolled 173 heavily pretreated R/M NPC patients and compared MRG003 to standard chemotherapy. The primary endpoint ORR assessed by blinded independent central review showed 30.2% vs 11.5% (difference 18.7%, 95%\u202fCI 7.0\u201330.5%, p=0.0025), meeting the pre\u2011specified significance threshold (p\u202f<\u202f0.05). The sample size and stratified randomization support the robustness of this finding.", "citations": [{"title": "NCT05126719 \u2013 Becotatug vedotin vs chemotherapy in R/M NPC", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05126719"}]}
{"abstract_id": 3632, "endpoint_id": 179, "truth": 1, "pred": 1, "blended_prob": 0.7719999999999999, "llm_prob": 0.82, "base_prob": 0.7, "base_note": "Base rate from phase_2 / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target braf v600e not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["single_arm_design_without_external_control"], "green": []}, "rationale": "The trial reports a mean surgical morbidity score reduction from 3.3 to 1.6 with a p\u2011value <0.01, meeting the predefined superiority criterion of p\u202f<\u202f0.05. Although the improvement is statistically significant, the single\u2011arm design without a concurrent control limits the robustness of the finding.", "citations": []}
{"abstract_id": 2882, "endpoint_id": 133, "truth": 0, "pred": 1, "blended_prob": 0.8404347826086958, "llm_prob": 0.85, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for TOP1 association comes only from trial abstract details, not from independent retrieved sources."], "green": []}, "rationale": "The phase\u20112 single\u2011arm SURE\u201102 trial evaluated TOP1 expression as a biomarker for ypT0 response and reported a non\u2011significant association (p = 0.79), which does not meet the predefined significance threshold (p < 0.05). The sample size for the biomarker analysis (23 patients) is modest, but the reported p\u2011value clearly indicates lack of statistical significance.", "citations": []}
{"abstract_id": 4719, "endpoint_id": 242, "truth": 0, "pred": 1, "blended_prob": 0.6661176470588235, "llm_prob": 0.62, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Outcome data not directly supported by retrieved citations"], "green": []}, "rationale": "The exploratory OS endpoint for osimertinib-treated patients with high Th7R showed a hazard ratio of 0.56 but a p\u2011value of 0.18, which does not meet the predefined significance threshold (p\u202f<\u202f0.05). The sample size (n\u224828 high\u2011Th7R patients) is modest, further limiting statistical power.", "citations": []}
{"abstract_id": 5227, "endpoint_id": 6, "truth": 0, "pred": 0, "blended_prob": 0.441, "llm_prob": 0.4, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": null, "flags": {"red": [], "yellow": ["limited direct evidence for OS outcome"], "green": []}, "rationale": "The trial reports a posterior probability of 55% that OS favors IFOS over CE, which is modest and below the adjusted prior (0.625\u202f\u00d7\u202f0.9 \u2248 0.56). As OS is a secondary endpoint in a relatively small phase\u202fII study (139 patients), the evidence does not convincingly support a true hazard ratio >\u202f1.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 1318, "endpoint_id": 82, "truth": 1, "pred": 1, "blended_prob": 0.7875, "llm_prob": 0.75, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Statistical significance of the ORR result is reported in the trial description but not directly supported by the retrieved external citations."], "green": []}, "rationale": "The randomized phase trial compared CCRT+tislelizumab versus CCRT alone in 53 LACC patients and reported an ORR of 100% vs 84.6% with a p\u2011value of 0.046, which meets the pre\u2011specified significance threshold (p\u202f<\u202f0.05) for the primary endpoint. The sample size is modest but sufficient to detect a statistically significant difference as reported.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 5217, "endpoint_id": 10, "truth": 1, "pred": 1, "blended_prob": 0.7695000000000001, "llm_prob": 0.72, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient direct citation for HTD determination; decision based on trial description rather than retrieved external sources."], "green": []}, "rationale": "The rolling six design escalated irinotecan to 50\u202fmg/m\u00b2/day with only one DLT observed at that level, meeting criteria to set the highest tested dose (HTD) at 50\u202fmg/m\u00b2/day as reported in the trial summary.", "citations": []}
{"abstract_id": 15, "endpoint_id": 333, "truth": 0, "pred": 1, "blended_prob": 0.5885714285714285, "llm_prob": 0.6, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient direct evidence from retrieved sources to confirm the reported p\u2011value"], "green": []}, "rationale": "The trial reports a p\u2011value of 0.094 for the global health status QoL endpoint, which does not meet the significance threshold of p\u202f<\u202f0.05. However, the specific statistical result is not present in the retrieved external evidence, reducing confidence in the assessment.", "citations": []}
{"abstract_id": 1274, "endpoint_id": 74, "truth": 1, "pred": 1, "blended_prob": 0.755, "llm_prob": 0.8, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target axl, mer, csf1r not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small single\u2011arm sample size (n=29) limits precision of activity estimate"], "green": []}, "rationale": "RECIST 1.1 is the standard radiologic response criterion for solid tumours and is routinely used to gauge preliminary anti\u2011tumour activity in early\u2011phase studies; the trial reports a confirmed CR and several SDs using this metric, supporting its suitability despite the modest, single\u2011arm cohort.", "citations": [{"title": "RECIST 1.1: Response Evaluation Criteria in Solid Tumors (Guidelines)", "url": "https://project.eortc.org/recist/wp-content/uploads/sites/4/2015/03/RECISTGuidelines.pdf"}]}
{"abstract_id": 2882, "endpoint_id": 136, "truth": 1, "pred": 0, "blended_prob": 0.49544827586206897, "llm_prob": 0.32, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient direct evidence from retrieved sources to confirm the reported cCR rate and stage\u2011specific counts."], "green": []}, "rationale": "The trial uses a two\u2011stage design requiring \u22657 complete clinical responses (cCR) among the first 23 patients to proceed. The interim report indicates a cCR rate of 38.7%, which exceeds the null hypothesis threshold (30%) but falls short of the alternative target (45%). Thus, while the first\u2011stage criterion appears met, the overall primary endpoint of achieving \u226545% cCR is not satisfied.", "citations": []}
{"abstract_id": 65, "endpoint_id": 159, "truth": 0, "pred": 1, "blended_prob": 0.7865714285714286, "llm_prob": 0.93, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target aromatase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The combined TEXT+SOFT analysis reports a 15\u2011year overall survival HR of 0.94 with a 95% CI of 0.80\u20131.11 for E+OFS versus T+OFS, which does not exclude 1, thus the superiority criterion is not met despite the large sample size and long follow\u2011up.", "citations": [{"title": "Long\u2011term follow\u2011up of the SOFT and TEXT randomized trials", "url": "http://www.clinicaltrials.gov/ct2/show/NCT00066690"}]}
{"abstract_id": 4719, "endpoint_id": 244, "truth": 0, "pred": 1, "blended_prob": 0.7441176470588236, "llm_prob": 0.75, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Limited sample size for the high\u2011Th2 subgroup and lack of direct citation for the reported P\u2011value"], "green": []}, "rationale": "The exploratory endpoint examines PFS in osimertinib\u2011treated patients with high Th2 levels. The reported hazard ratio (HR\u202f=\u202f1.78) was accompanied by a P\u2011value of 0.11, which does not meet the predefined significance threshold (p\u202f<\u202f0.05). The subgroup size is modest (\u224827 patients), reducing statistical power and increasing uncertainty.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 2120, "endpoint_id": 272, "truth": 1, "pred": 1, "blended_prob": 0.8944347826086956, "llm_prob": 0.94, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["biomarker tier green"]}, "rationale": "The trial reports that ctDNA mutation number, abundance, and level all decreased with therapeutic response with P\u202f<\u202f0.001, which meets the predefined significance threshold (p\u202f<\u202f0.05) for this exploratory endpoint despite the modest sample size.", "citations": []}
{"abstract_id": 65, "endpoint_id": 158, "truth": 0, "pred": 1, "blended_prob": 0.8045714285714285, "llm_prob": 0.96, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target aromatase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The combined TEXT+SOFT analysis reports a 15\u2011year overall survival HR of 0.94 with a 95% CI of 0.80\u20131.11 for exemestane\u202f+\u202fOFS versus tamoxifen\u202f+\u202fOFS, which includes 1, indicating that superiority for OS is not demonstrated.", "citations": [{"title": "Long\u2011term overall survival results from the TEXT and SOFT trials", "url": "http://www.clinicaltrials.gov/ct2/show/NCT00066690"}, {"title": "Long\u2011term overall survival results from the TEXT and SOFT trials", "url": "http://www.clinicaltrials.gov/ct2/show/NCT00066703"}]}
{"abstract_id": 4860, "endpoint_id": 303, "truth": 0, "pred": 1, "blended_prob": 0.8150000000000001, "llm_prob": 0.9, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target gut microflora and metabolites not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient external evidence; the reported p\u2011value for median onset time is not present in the retrieved snippets"], "green": []}, "rationale": "The study reports a median onset time of irAEs of 14.9 weeks in the GQT arm versus 8.7 weeks in control with a p\u2011value of 0.807, which fails to meet the predefined significance criterion (p\u202f<\u202f0.05). With 94 randomized patients (47 per arm), the sample size is modest and the non\u2011significant result indicates the endpoint is not statistically supported.", "citations": []}
{"abstract_id": 2744, "endpoint_id": 284, "truth": 1, "pred": 1, "blended_prob": 0.6075, "llm_prob": 0.45, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target pauf not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["very small sample size (n=6) limits robustness of safety conclusions"], "green": []}, "rationale": "The 3+3 dose\u2011escalation design evaluated safety in six patients (3 per dose level) and reported no dose\u2011limiting toxicities or serious adverse events, with most treatment\u2011emergent events being grade 1\u20112, which satisfies the primary safety endpoint for a phase\u202f1 study, though the limited cohort size reduces confidence.", "citations": []}
{"abstract_id": 5327, "endpoint_id": 306, "truth": 0, "pred": 1, "blended_prob": 0.7227, "llm_prob": 0.88, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "yellow", "reason": "Target gd2 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size; single\u2011arm design; borderline p\u2011value (0.054)"], "green": []}, "rationale": "The trial reports 12\u2011month OS rates of 92.3% vs 59.3% with a p\u2011value of 0.054, which does not meet the pre\u2011specified significance threshold of p\u202f<\u202f0.05. The small evaluable cohort (25 patients) and lack of a randomized comparator further limit confidence in the result.", "citations": [{"title": "NCT06013618 \u2013 Naxitamab plus GM\u2011CSF \u00b1 sintilimab in refractory/progressive neuroblastoma", "url": "http://www.clinicaltrials.gov/ct2/show/NCT06013618"}]}
{"abstract_id": 327, "endpoint_id": 17, "truth": 1, "pred": 1, "blended_prob": 0.7204347826086956, "llm_prob": 0.65, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Insufficient external citation for the reported association"], "green": []}, "rationale": "The phase\u2011II single\u2011arm trial of camrelizumab\u202f+\u202fnab\u2011paclitaxel/cisplatin in untreated mTNBC reported a hazard ratio of 11.6 (95%\u202fCI\u202f2.4\u201155.7, p\u202f=\u202f0.002) for DNA\u2011repair pathway activation versus PFS, meeting the predefined superiority threshold (p\u202f<\u202f0.05). The sample size (90 patients) and clear statistical significance support the endpoint claim, though no independent citation is available in the retrieved evidence.", "citations": []}
{"abstract_id": 1088, "endpoint_id": 61, "truth": 1, "pred": 1, "blended_prob": 0.8277777777777777, "llm_prob": 0.75, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target b7h3 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size (n=9) and limited safety data"], "green": []}, "rationale": "The phase 1 single\u2011arm study enrolled 9 evaluable patients; only one DLT (grade\u202f3 hypertension) was observed at the recommended phase\u202f2 dose, with no further DLTs in the expanded cohort, indicating that the safety primary endpoint was met despite the limited sample size.", "citations": []}
{"abstract_id": 3359, "endpoint_id": 170, "truth": 1, "pred": 1, "blended_prob": 0.876, "llm_prob": 0.96, "base_prob": 0.75, "base_note": "Base rate from phase_2 / co-primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The single\u2011arm phase\u202f2 study met its pre\u2011specified decision rule for the 6\u2011month PFS co\u2011primary endpoint: 16 of 30 patients (53%) were progression\u2011free at 6\u202fmonths, exceeding the required minimum of 6 patients and the null hypothesis threshold of 10%, thus supporting further development of pembrolizumab\u202f+\u202flenvatinib in CCOC.", "citations": [{"title": "NCT05296512", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05296512"}]}
{"abstract_id": 15, "endpoint_id": 332, "truth": 1, "pred": 1, "blended_prob": 0.6605714285714286, "llm_prob": 0.72, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Limited direct citation for the specific p\u2011value; reliance on trial summary details"], "green": []}, "rationale": "The trial report states that erectile dysfunction\u2011related bother was higher in the PF arm with a p\u2011value of 0.018, which meets the p\u202f<\u202f0.05 significance criterion for this secondary endpoint, despite the small sample size (49 patients).", "citations": []}
{"abstract_id": 1608, "endpoint_id": 93, "truth": 1, "pred": 1, "blended_prob": 0.6975, "llm_prob": 0.6, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target kras g12d not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Limited direct evidence for DLT outcome; decision based on trial summary"], "green": []}, "rationale": "The phase 1a portion enrolled 18 patients across dose levels up to 600\u202fmg BID and reported no dose\u2011limiting toxicities, indicating the primary endpoint of absence of DLT was achieved. However, the supporting evidence is limited to the trial summary without independent citation.", "citations": []}
{"abstract_id": 3905, "endpoint_id": 198, "truth": 1, "pred": 1, "blended_prob": 0.635, "llm_prob": 0.6, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient citation support for molecular remission outcome"], "green": []}, "rationale": "The single\u2011arm study enrolled ten high\u2011risk APL patients and reported that all achieved molecular remission by day 28 of the first consolidation cycle, satisfying the decision rule. However, the evidence is limited to a small, uncontrolled cohort and no external citations corroborate the molecular remission claim, reducing confidence.", "citations": []}
{"abstract_id": 1152, "endpoint_id": 65, "truth": 1, "pred": 1, "blended_prob": 0.7377777777777778, "llm_prob": 0.6, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Evidence for safety outcome not directly cited from retrieved sources"], "green": []}, "rationale": "The trial reports no dose\u2011limiting toxicities, no treatment\u2011related adverse events \u2265 grade 3, and no discontinuations due to adverse events, indicating that safety and tolerability criteria per NCI\u2011CTCAE v5.0 were met, but the lack of directly cited evidence lowers confidence.", "citations": []}
{"abstract_id": 5216, "endpoint_id": 3, "truth": 1, "pred": 1, "blended_prob": 0.6975, "llm_prob": 0.6, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target alk-fusion proteins not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Safety data not present in retrieved external evidence; assessment relies solely on trial summary"], "green": []}, "rationale": "The trial reports 1 DLT among 21 safety\u2011evaluable patients and Grade \u22653 related AEs in 5 patients (23.8%), with most AEs being Grade 1\u20112, indicating a favorable safety profile for the primary safety endpoint, though external citations are lacking.", "citations": []}
{"abstract_id": 3719, "endpoint_id": 288, "truth": 1, "pred": 1, "blended_prob": 0.647, "llm_prob": 0.62, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["No direct citation for fatigue outcome; inference based on trial details not present in retrieved evidence."], "green": []}, "rationale": "The trial reports a fatigue improvement of 13% vs 9% with a p\u2011value of 0.038, which meets the predefined significance threshold (p<0.05). However, the sample size is modest (25 per arm), limiting precision, and the specific fatigue result is not corroborated by the retrieved external evidence.", "citations": []}
{"abstract_id": 4375, "endpoint_id": 229, "truth": 1, "pred": 1, "blended_prob": 0.861448275862069, "llm_prob": 0.93, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["small sample size"], "green": []}, "rationale": "The randomized phase\u2011II study reported a hazard ratio of 0.25 for progression\u2011free survival with a 95% confidence interval of 0.07\u20110.90 and a p\u2011value of 0.034, which satisfies the pre\u2011specified significance criterion of p\u202f<\u202f0.05 for the primary endpoint.", "citations": [{"title": "Induction toripalimab plus chemotherapy versus chemotherapy alone in bulky unresectable stage III NSCLC (NCT05888402)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05888402"}]}
{"abstract_id": 390, "endpoint_id": 26, "truth": 1, "pred": 1, "blended_prob": 0.8499999999999999, "llm_prob": 0.95, "base_prob": 0.7, "base_note": "Base rate from phase_2 / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["non\u2011randomized sequential cohorts; single\u2011arm design may introduce bias"], "green": []}, "rationale": "The study reports a hazard ratio for overall survival of 0.50 with a 95% CI of 0.26\u20110.98 and a p\u2011value of 0.043, satisfying the predefined superiority criteria (p\u202f<\u202f0.05 and CI upper bound\u202f<\u202f1). Although the sample size is modest (n=50) and the comparison is between sequential cohorts rather than a randomized control, the statistical evidence meets the decision rule.", "citations": [{"title": "Phase II trial of pembrolizumab plus nab\u2011paclitaxel with immunotherapy vs chemotherapy run\u2011in in mTNBC (NCT02752685)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT02752685"}]}
{"abstract_id": 41, "endpoint_id": 317, "truth": 0, "pred": 0, "blended_prob": 0.34172307692307696, "llm_prob": 0.12, "base_prob": 0.7692307692307693, "base_note": "Base rate from phase_2 / secondary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["secondary endpoint; modest sample size"], "green": []}, "rationale": "The trial reports a median 1st PFS of 4.1\u202fmo (panitumumab) vs 2.4\u202fmo (regorafenib) with a hazard ratio of 1.23 (95%\u202fCI\u202f0.93\u20131.64) and p\u2011values of 0.15 (Cox) and 0.12 (log\u2011rank), both above the 0.05 threshold required for superiority, indicating the hypothesis is not met.", "citations": [{"title": "LBA3515 \u2013 PARERE trial results (NCT04787341)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04787341"}]}
{"abstract_id": 3905, "endpoint_id": 199, "truth": 1, "pred": 1, "blended_prob": 0.755, "llm_prob": 0.8, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["small sample size (n=10) limits robustness of safety conclusion"], "green": []}, "rationale": "The single\u2011arm study of 10 high\u2011risk APL patients reported no cases of prolonged neutropenia (>28 days). While the endpoint was met, the very small cohort reduces confidence in the generalizability of this safety finding.", "citations": []}
{"abstract_id": 41, "endpoint_id": 315, "truth": 1, "pred": 1, "blended_prob": 0.789923076923077, "llm_prob": 0.95, "base_prob": 0.7692307692307693, "base_note": "Base rate from phase_2 / secondary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["statistically significant DCR difference with p < 0.01"]}, "rationale": "The randomized phase II trial compared panitumumab followed by regorafenib versus the reverse sequence in chemorefractory RAS/BRAF wild\u2011type mCRC. The first\u2011line disease control rate was 59.4% vs 31.8% (OR 0.32, 95%\u202fCI 0.18\u20130.56) with a reported p\u202f<\u202f0.01, satisfying the superiority hypothesis threshold of p\u202f<\u202f0.01 for this secondary endpoint.", "citations": [{"title": "PARERE (NCT04787341) \u2013 1st disease control rate results", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04787341"}]}
{"abstract_id": 92, "endpoint_id": 164, "truth": 0, "pred": 1, "blended_prob": 0.5295000000000001, "llm_prob": 0.32, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient direct evidence from retrieved sources to confirm trial outcome"], "green": []}, "rationale": "The trial aimed to detect a 31% difference in RCB 0/I rates with 80% power. The reported stratified risk difference was -18.8% (p=0.068), which does not meet the predefined significance threshold or magnitude, suggesting the primary endpoint was not achieved. However, the specific outcome data are not present in the retrieved evidence, reducing confidence.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 73, "endpoint_id": 163, "truth": 0, "pred": 1, "blended_prob": 0.6005714285714285, "llm_prob": 0.62, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient direct evidence for OS hazard ratio in retrieved snippets"], "green": []}, "rationale": "The decision rule requires the upper bound of the 95% CI for the OS hazard ratio to be <1.0. The trial abstract reports an OS HR of 0.79 with a 95% CI of 0.50\u20111.27, which does not meet the criterion. However, the hazard ratio details are not present in the retrieved evidence, reducing confidence.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 3764, "endpoint_id": 293, "truth": 1, "pred": 1, "blended_prob": 0.73, "llm_prob": 0.8, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["small sample size (n=20) and single\u2011arm design limit robustness"], "green": []}, "rationale": "The trial reports that the combination of tislelizumab and TP chemotherapy did not increase the incidence of adverse events and no grade\u202f3/4 treatment\u2011related adverse events were observed, directly satisfying the predefined safety decision rule. However, the evidence is based on a single\u2011arm study with only 20 participants, which reduces confidence in the generalizability of the safety conclusion.", "citations": []}
{"abstract_id": 1052, "endpoint_id": 53, "truth": 0, "pred": 1, "blended_prob": 0.851, "llm_prob": 0.96, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": [], "green": ["clear subgroup analysis"]}, "rationale": "The CATNON phase III trial provides a subgroup analysis for IDH\u2011mutant patients who received both adjuvant and concurrent temozolomide. The reported hazard ratio for concurrent TMZ in this group is 0.92 with a 95% CI of 0.63\u20111.36 and a p\u2011value of 0.69, which fails to meet the predefined superiority criteria (p\u202f<\u202f0.05 and CI excluding 1). Hence, concurrent TMZ does not demonstrate a statistically significant benefit in the IDHmt\u202f+\u202fadjuvant TMZ subgroup.", "citations": [{"title": "CATNON trial final analysis \u2013 Benefit of temozolomide in IDH\u2011mutant anaplastic glioma", "url": "http://www.clinicaltrials.gov/ct2/show/NCT00626990"}]}
{"abstract_id": 46, "endpoint_id": 309, "truth": 1, "pred": 1, "blended_prob": 0.8134482758620689, "llm_prob": 0.85, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target tumor angiogenesis and proliferation not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["limited direct citation of trial outcome"], "green": ["adequate sample size", "statistically significant HR"]}, "rationale": "The randomized, double\u2011blind phase II trial enrolled 153 patients (\u2248150 planned) and met its pre\u2011specified primary endpoint: IRC\u2011assessed PFS showed a hazard ratio of 0.59 (95%\u202fCI\u202f0.42\u20110.85) with p\u202f=\u202f0.0043, closely matching the target HR of 0.58 at a two\u2011sided 5% alpha. The design, sample size, and independent review of progression are consistent with FDA guidance for robust oncology endpoints.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 6196, "endpoint_id": 40, "truth": 1, "pred": 1, "blended_prob": 0.6975, "llm_prob": 0.6, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Primary endpoint result (p\u2011value) not present in retrieved evidence; inference based on provided trial summary rather than cited data."], "green": []}, "rationale": "The trial reports a primary endpoint of nausea prevention with a p\u2011value <0.001, which meets the superiority criterion of p\u202f<\u202f0.05. However, the retrieved evidence does not contain the specific result, so confidence is moderated.", "citations": [{"title": "Clinical Trial Design and Drug Approval in Oncology", "url": "https://doi.org/10.6004/jadpro.2020.11.7.7"}]}
{"abstract_id": 3925, "endpoint_id": 204, "truth": 1, "pred": 1, "blended_prob": 0.8041176470588236, "llm_prob": 0.85, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cyp3a not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size; exploratory endpoint"], "green": []}, "rationale": "The trial reports a median Cmax of 1.435\u202f\u00b5g/mL vs 3.63\u202f\u00b5g/mL with a p\u2011value of 0.002, which meets the predefined significance threshold (p\u202f<\u202f0.05). Despite the statistically significant difference, the small cohort (n=31) and exploratory nature of the endpoint warrant caution.", "citations": []}
{"abstract_id": 6196, "endpoint_id": 39, "truth": 1, "pred": 1, "blended_prob": 0.8270000000000001, "llm_prob": 0.92, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for the endpoint outcome is not present in the retrieved external sources; reliance is on the provided trial description."], "green": []}, "rationale": "The trial reports a statistically significant reduction in patients experiencing >15 vomiting episodes (9.2% vs 2%, p=0.002), which meets the superiority criterion of p<0.05. The sample size (n=301) is adequate for a Phase III randomized placebo-controlled design, supporting robustness of the finding.", "citations": []}
{"abstract_id": 3065, "endpoint_id": 147, "truth": 1, "pred": 1, "blended_prob": 0.6399999999999999, "llm_prob": 0.6, "base_prob": 0.7, "base_note": "Base rate from phase_2 / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Outcome significance not directly supported by retrieved citations; relies on trial summary details."], "green": []}, "rationale": "The randomized phase 2 trial reported median overall survival of 10.2 months with niraparib alone versus 24.3 months with niraparib plus cetrelimab, with a reported p\u2011value of 0.01, meeting the predefined significance threshold (p\u202f<\u202f0.05). However, the retrieved external evidence does not contain the trial data, so the assessment rests on the provided trial summary.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 3614, "endpoint_id": 286, "truth": 1, "pred": 1, "blended_prob": 0.675448275862069, "llm_prob": 0.62, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cyclin-dependent kinase 4/6 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient direct citation of trial outcome in retrieved evidence"], "green": []}, "rationale": "The single\u2011arm phase\u202fII trial enrolled 28 ovarian cancer patients with CDKN2A alterations and used a Simon two\u2011stage design requiring \u22657 disease control events to reject the null. The reported disease control rate of 37% implies at least 10 patients achieved DC, exceeding the threshold, and the null hypothesis was statistically rejected (p=0.005). The sample size and predefined decision rule provide a robust assessment of the primary endpoint.", "citations": []}
{"abstract_id": 2744, "endpoint_id": 285, "truth": 1, "pred": 1, "blended_prob": 0.7635000000000001, "llm_prob": 0.71, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target pauf not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Limited sample size and lack of external citation for tolerability data"], "green": []}, "rationale": "The phase 1/2a dose\u2011escalation study enrolled six patients across two dose levels and reported no dose\u2011limiting toxicities, no serious adverse events, and only grade 1\u20112 treatment\u2011related events, indicating acceptable tolerability per the predefined 3+3 design, though the very small cohort limits robustness.", "citations": []}
{"abstract_id": 4112, "endpoint_id": 218, "truth": 1, "pred": 1, "blended_prob": 0.6697058823529413, "llm_prob": 0.75, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "yellow", "reason": "Target cd20, cd47 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["single_arm_design", "small_sample_size"], "green": []}, "rationale": "The trial report states that there were no significant differences in PK exposure between amulirafusp alfa monotherapy and its combination with lenalidomide, directly satisfying the decision rule. However, the study is a single\u2011arm design with only 34 enrolled patients, limiting the robustness of the comparison.", "citations": []}
{"abstract_id": 3359, "endpoint_id": 169, "truth": 1, "pred": 1, "blended_prob": 0.732, "llm_prob": 0.72, "base_prob": 0.75, "base_note": "Base rate from phase_2 / co-primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Limited direct citation for ORR outcome; decision based on trial summary details."], "green": []}, "rationale": "The single\u2011arm phase\u202f2 study enrolled 30 patients and reported 9 confirmed objective responses (2 CR, 7 PR), exceeding the pre\u2011specified threshold of 5 responses required to deem the pembrolizumab/lenvatinib combination worthy of further study. The sample size and clear response definition support a robust assessment of the ORR endpoint.", "citations": []}
{"abstract_id": 5020, "endpoint_id": 252, "truth": 1, "pred": 1, "blended_prob": 0.7977777777777777, "llm_prob": 0.7, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target mbil15 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Outcome inference relies on trial summary rather than direct cited data"], "green": []}, "rationale": "The phase 1 data report no dose\u2011limiting toxicities, no treatment\u2011related mortality, and well\u2011tolerated acetazolamide redosing, with six patients successfully treated at the defined RP2D, indicating the tolerability endpoint was met and an RP2D was established.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 291, "endpoint_id": 14, "truth": 1, "pred": 1, "blended_prob": 0.7095, "llm_prob": 0.62, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cdk4/6 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Evidence for the specific PFS result is only from trial details, not from the retrieved external sources."], "green": []}, "rationale": "The single\u2011arm phase II component enrolled 77 first\u2011line HR+/HER2+ advanced breast cancer patients and reported a median PFS of 30.4 months, clearly exceeding the prespecified target improvement from 8 to 12 months, indicating the primary endpoint was met despite the lack of external citation.", "citations": [{"title": "Cancer Drug Approval Endpoints \u2013 FDA Guidance", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 1052, "endpoint_id": 58, "truth": 0, "pred": 1, "blended_prob": 0.8330000000000001, "llm_prob": 0.93, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "In the intent\u2011to\u2011treat population the hazard ratio for overall survival with concurrent temozolomide was 0.906 (95%\u202fCI 0.760\u20131.082; p=0.28), which fails to achieve the required p\u202f<\u202f0.05 and a confidence interval excluding 1, indicating no superiority over radiotherapy alone.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 1292, "endpoint_id": 72, "truth": 1, "pred": 1, "blended_prob": 0.799, "llm_prob": 0.85, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["manageable safety observed in phase\u20111 cohort"]}, "rationale": "The phase\u20111 single\u2011arm study enrolled 79 heavily pretreated patients and reported no dose\u2011limiting toxicities, with grade\u202f3 treatment\u2011related adverse events in only 7 patients and a clear statement that LB1410 has a manageable safety profile, satisfying the primary safety decision rule.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics | FDA Guidance", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 233, "endpoint_id": 260, "truth": 1, "pred": 1, "blended_prob": 0.6796923076923077, "llm_prob": 0.62, "base_prob": 0.7692307692307693, "base_note": "Base rate from phase_2 / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target her2 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Insufficient direct safety evidence in retrieved citations; decision based on abstract summary not present in sources"], "green": []}, "rationale": "The trial reports no treatment-related deaths and only one SAE (herpes zoster) with common mild AEs, indicating a manageable safety profile that satisfies the decision rule, but the retrieved evidence does not directly contain these safety details, lowering confidence.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 3679, "endpoint_id": 189, "truth": 1, "pred": 1, "blended_prob": 0.7, "llm_prob": 0.7, "base_prob": 0.7, "base_note": "Base rate from phase_2 / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient direct citation for adverse event data"], "green": []}, "rationale": "The study reports grade 3\u20114 acute treatment\u2011related adverse events in 66.7% of the toripalimab arm versus 61.3% of the standard arm (p = 0.496), which does not reach statistical significance (p \u2265 0.05). Accordingly, the decision rule of no significant difference in harm is met.", "citations": []}
{"abstract_id": 107, "endpoint_id": 173, "truth": 1, "pred": 1, "blended_prob": 0.7861176470588235, "llm_prob": 0.82, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Limited direct evidence for the specific biomarker\u2011pCR association; inference based on trial summary rather than cited source."], "green": []}, "rationale": "The trial reports a p\u2011value of 0.041 for the lower pCR rate in TASOR2 or MST1R mutated patients, which meets the <0.05 significance threshold. Although the specific biomarker result is not directly cited in the retrieved literature, the use of pCR as a validated neoadjuvant endpoint in TNBC is supported.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 7, "endpoint_id": 329, "truth": 1, "pred": 1, "blended_prob": 0.7985714285714285, "llm_prob": 0.95, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target poly (adp-ribose) polymerase (parp)-1/2 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Biomarker tier is YELLOW; PARP alteration not an established predictive marker"], "green": []}, "rationale": "The double\u2011blind, placebo\u2011controlled phase\u202f3 AMPLITUDE trial randomized 696 HRR\u2011altered mCSPC patients and showed a statistically significant improvement in time to symptomatic progression (HR\u202f0.50, p\u202f<\u202f0.0001), meeting the predefined superiority criterion (p\u202f<\u202f0.05). Sample size and event accrual are adequate, and the endpoint was prospectively defined and analyzed with stratified Cox models.", "citations": [{"title": "AMPLITUDE trial (NCT04497844) \u2013 LBA5006 abstract", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04497844"}]}
{"abstract_id": 41, "endpoint_id": 316, "truth": 1, "pred": 1, "blended_prob": 0.7953230769230769, "llm_prob": 0.96, "base_prob": 0.7692307692307693, "base_note": "Base rate from phase_2 / secondary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": [], "green": ["robust statistical significance for ORR"]}, "rationale": "The randomized phase II trial reported a first\u2011line objective response rate of 16.0% with panitumumab versus 1.9% with regorafenib (OR 0.1, 95%\u202fCI 0.01\u20130.44) and a p\u2011value <\u202f0.01, satisfying the predefined superiority criterion (p\u202f<\u202f0.01) for this secondary endpoint.", "citations": [{"title": "PARERE trial (LBA3515) \u2013 1st ORR results", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04787341"}]}
{"abstract_id": 327, "endpoint_id": 22, "truth": 1, "pred": 1, "blended_prob": 0.6904347826086956, "llm_prob": 0.6, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["single\u2011arm design without a comparator; no supporting citation from retrieved evidence"], "green": []}, "rationale": "The exploratory analysis reported a statistically significant longer PFS for patients with PD\u2011L1 CPS \u226510 versus lower CPS (13.7 vs 11.4 months, p = 0.039), which meets the predefined superiority threshold (p < 0.05), though the single\u2011arm nature of the study limits the robustness of the finding.", "citations": []}
{"abstract_id": 6196, "endpoint_id": 37, "truth": 1, "pred": 0, "blended_prob": 0.455, "llm_prob": 0.3, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient evidence: no between\u2011group p\u2011value for mean depression score provided"], "green": []}, "rationale": "The trial reports within\u2011arm changes in mean depression scores with p<0.001, but does not provide a direct between\u2011group comparison p\u2011value required to assess superiority (p<0.05). Without that evidence, the superiority criterion cannot be confirmed.", "citations": []}
{"abstract_id": 4334, "endpoint_id": 221, "truth": 1, "pred": 1, "blended_prob": 0.7377777777777778, "llm_prob": 0.6, "base_prob": 0.9444444444444444, "base_note": "Base rate from phase_1 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target bcma not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Limited direct evidence linking the reported AE data to the primary endpoint; reliance on trial summary without external validation."], "green": []}, "rationale": "The phase\u20111 dose\u2011escalation study defined the primary endpoint as incidence of adverse events, including DLTs, and reported no DLTs and detailed AE frequencies, indicating the endpoint was assessed and met according to the study design, though the small sample size (n=18) limits robustness.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 1608, "endpoint_id": 94, "truth": 1, "pred": 0, "blended_prob": 0.43, "llm_prob": 0.3, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target kras g12d not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient direct evidence on safety outcomes from the provided trial data"], "green": []}, "rationale": "The trial abstract reports only grade 1\u20112 TRAEs and no grade \u22653 events, suggesting an acceptable safety profile, but none of the retrieved evidence snippets contain these safety details, limiting confidence in the assessment.", "citations": [{"title": "Clinical Trial Design and Drug Approval in Oncology", "url": "https://doi.org/10.6004/jadpro.2020.11.7.7"}, {"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 19, "endpoint_id": 344, "truth": 0, "pred": 1, "blended_prob": 0.855448275862069, "llm_prob": 0.92, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["crossover may have diluted the OS signal; supplementary analysis excludes crossover but is not the primary analysis"], "green": []}, "rationale": "The primary ITT analysis of overall survival shows a hazard ratio of 0.73 with a 95% CI of 0.48\u20131.12, which includes 1 and therefore does not meet the pre\u2011specified significance criterion. Although a post\u2011hoc supplementary analysis (HR\u202f0.59, 95%\u202fCI\u202f0.37\u20130.93) excludes 1, it is not the primary endpoint analysis, so the OS result is not statistically significant per the decision rule.", "citations": [{"title": "NCT05126719 \u2013 Becotatug vedotin (MRG003) vs chemotherapy in heavily pretreated R/M NPC", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05126719"}, {"title": "Table of OS results (ITT and supplementary analysis)", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05126719"}]}
{"abstract_id": 73, "endpoint_id": 161, "truth": 1, "pred": 0, "blended_prob": 0.45866666666666667, "llm_prob": 0.32, "base_prob": 0.6666666666666666, "base_note": "Base rate from phase_3_plus / post-hoc (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Insufficient specific trial data in retrieved evidence to confirm HR confidence interval for BCFI"], "green": []}, "rationale": "The decision rule requires the upper bound of the 95% CI for the BCFI hazard ratio to be below 1.0. The trial abstract reports such a result only for a high\u2011risk subgroup, but the retrieved evidence does not contain those specific hazard ratio values, leaving the superiority claim unsupported by the available citations.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 3123, "endpoint_id": 151, "truth": 1, "pred": 1, "blended_prob": 0.502, "llm_prob": 0.42, "base_prob": 0.625, "base_note": "Base rate from unknown / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target parp, ezh2 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Insufficient direct evidence from retrieved sources to robustly assess safety; reliance on trial description not cited."], "green": []}, "rationale": "The trial reports Grade \u22653 treatment\u2011related adverse events in 59% of patients and dose reductions in 52%, which the authors describe as an acceptable safety profile for a heavily pretreated population, suggesting preliminary safety is met, but the lack of cited safety data in the retrieved evidence reduces confidence.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 15, "endpoint_id": 331, "truth": 1, "pred": 1, "blended_prob": 0.6965714285714285, "llm_prob": 0.78, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["insufficient citation"], "green": []}, "rationale": "The study reports Grade 3/4 hematological toxicities of 28.6% versus 4.5% with a p\u2011value of 0.033, which satisfies the pre\u2011specified significance criterion (p < 0.05) despite the modest sample size of 49 patients.", "citations": []}
{"abstract_id": 3905, "endpoint_id": 196, "truth": 1, "pred": 1, "blended_prob": 0.725, "llm_prob": 0.75, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["small sample size (n=10)", "no external evidence retrieved for cardiotoxicity outcome"], "green": []}, "rationale": "The single\u2011arm study of ten high\u2011risk APL patients reported no instances of cardiotoxicity among participants receiving venetoclax with ATRA and ATO, satisfying the decision rule. However, the very limited sample size and lack of corroborating external evidence reduce confidence in the robustness of this finding.", "citations": []}
{"abstract_id": 2120, "endpoint_id": 273, "truth": 1, "pred": 1, "blended_prob": 0.6904347826086956, "llm_prob": 0.6, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["insufficient citation for ctDNA endpoint results"], "green": []}, "rationale": "The trial reports that ctDNA mutation number, abundance, and level all decreased with therapeutic response with P\u202f<\u202f0.001, meeting the p\u202f<\u202f0.05 decision rule; however, the retrieved evidence does not include the specific trial data, reducing confidence.", "citations": []}
{"abstract_id": 1052, "endpoint_id": 56, "truth": 0, "pred": 1, "blended_prob": 0.647, "llm_prob": 0.62, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for the specific HR and p-value is not present in the retrieved external sources; relied on trial abstract provided in prompt."], "green": []}, "rationale": "The concurrent temozolomide arm in the IDH\u2011mutant subgroup showed an HR of 0.81 with a 95% CI of 0.63\u20111.04 and a p\u2011value of 0.09, which does not meet the superiority criteria of p\u202f<\u202f0.05 and a confidence interval excluding 1.", "citations": []}
{"abstract_id": 65, "endpoint_id": 157, "truth": 1, "pred": 1, "blended_prob": 0.8045714285714285, "llm_prob": 0.96, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target aromatase not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The SOFT trial reports a hazard ratio for invasive breast cancer\u2011free interval of 0.82 with a 95% CI of 0.69\u20110.98 for tamoxifen\u202f+\u202fOFS versus tamoxifen alone, meeting the predefined superiority criterion (CI excludes 1). The large sample size (\u22483,000 patients) and long median follow\u2011up (15\u202fyears) provide robust evidence for this endpoint.", "citations": [{"title": "Long\u2011term follow\u2011up of the SOFT and TEXT randomized trials", "url": "http://www.clinicaltrials.gov/ct2/show/NCT00066690"}]}
{"abstract_id": 2877, "endpoint_id": 131, "truth": 1, "pred": 1, "blended_prob": 0.6386666666666667, "llm_prob": 0.62, "base_prob": 0.6666666666666666, "base_note": "Base rate from phase_3_plus / key secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Missing direct OS hazard ratio evidence in retrieved sources"], "green": []}, "rationale": "The trial is a phase\u20113, double\u2011blind, placebo\u2011controlled study with 994 participants, evaluating overall survival as a key secondary endpoint. The reported OS hazard ratio of 0.66 with a 95% CI upper bound of 0.90 meets the predefined superiority criterion (upper bound\u202f<\u202f1.0). The large sample size and mature follow\u2011up (median 69.5\u202fmonths) support robustness, though the specific HR data are not present in the retrieved evidence.", "citations": []}
{"abstract_id": 2958, "endpoint_id": 145, "truth": 0, "pred": 1, "blended_prob": 0.735448275862069, "llm_prob": 0.72, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Evidence for the exact response count is not present in the retrieved citations; decision relies on trial summary provided in the prompt."], "green": []}, "rationale": "The Simon two\u2011stage design required \u22654 objective responses among the first 19 patients to proceed. The trial reported only 3 partial responses (15.8%) in Stage\u202f1, thus the predefined efficacy threshold was not met and recruitment was halted. The primary endpoint (ORR per RECIST\u202fv1.1) is appropriate for a single\u2011arm phase\u202f2 study.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 4719, "endpoint_id": 245, "truth": 1, "pred": 1, "blended_prob": 0.5641176470588236, "llm_prob": 0.45, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target egfr has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Insufficient direct citation of the PFS result in the retrieved evidence"], "green": []}, "rationale": "The trial reports a PFS hazard ratio of 0.38 with a p\u2011value of 0.006 for osimertinib\u2011treated patients with high Th7R, which meets the p\u202f<\u202f0.05 significance criterion, but the retrieved evidence does not contain a direct excerpt confirming this result, reducing confidence.", "citations": []}
{"abstract_id": 1895, "endpoint_id": 107, "truth": 1, "pred": 1, "blended_prob": 0.737503448275862, "llm_prob": 0.86, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": null, "flags": {"red": [], "yellow": ["refractory_population"], "green": ["decision_rule_met"]}, "rationale": "The Simon two\u2011stage design required \u22654 disease\u2011controlled patients among 25 to declare success. The reported disease control rate was 60% (15/25), clearly exceeding the threshold, indicating a positive trial despite the refractory patient population which typically lowers response expectations.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 5023, "endpoint_id": 249, "truth": 1, "pred": 1, "blended_prob": 0.5461176470588236, "llm_prob": 0.42, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target il-6 receptor not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["insufficient evidence for a statistically significant change in circulating IL-6 mediators"], "green": []}, "rationale": "The trial abstract reports a significant reduction in IL-6Ra and IL-4 (P < 0.05), but none of the retrieved evidence snippets contain this data. Without a citation from the provided evidence, we cannot confirm that the exploratory endpoint met the predefined significance criterion.", "citations": [{"title": "iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics", "url": "https://recist.eortc.org/recist/wp-content/uploads/sites/4/2017/03/Manuscript_IRECIST_Lancet-Oncology_Seymour-et-al_revision_FINAL_clean_nov25.pdf"}]}
{"abstract_id": 14, "endpoint_id": 311, "truth": 0, "pred": 1, "blended_prob": 0.6920000000000001, "llm_prob": 0.62, "base_prob": 0.8, "base_note": "Base rate from phase_3_plus / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target vegfr not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["insufficient citation of trial-specific HR and CI; decision based on trial summary not present in retrieved evidence"], "green": []}, "rationale": "The trial reports an IRC-assessed PFS hazard ratio of 1.00 with a 95% CI of 0.84\u20111.18. Although the point estimate meets the non\u2011inferiority margin (HR \u22641.09), the upper confidence bound exceeds the margin, which under standard non\u2011inferiority criteria means non\u2011inferiority is not demonstrated. Therefore the primary endpoint does not satisfy the decision rule.", "citations": [{"title": "Clinical Trial Design and Drug Approval in Oncology", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 2958, "endpoint_id": 146, "truth": 1, "pred": 1, "blended_prob": 0.7756923076923077, "llm_prob": 0.78, "base_prob": 0.7692307692307693, "base_note": "Base rate from phase_2 / secondary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Safety conclusion not directly supported by retrieved external citations"], "green": []}, "rationale": "The trial reports that atezolizumab was well tolerated with no new safety signals, satisfying the secondary endpoint decision rule of no unexpected safety issues; however, the supporting evidence is limited to the trial abstract and not corroborated by external retrieved sources.", "citations": []}
{"abstract_id": 6278, "endpoint_id": 51, "truth": 0, "pred": 1, "blended_prob": 0.6785714285714285, "llm_prob": 0.75, "base_prob": 0.5714285714285714, "base_note": "Base rate from phase_3_plus / secondary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["small sample size (n=40) and reliance on subscale p\u2011values rather than the primary QoL composite"], "green": []}, "rationale": "The secondary QoL endpoint requires a statistically significant superiority (p\u202f<\u202f\u03b1) for the overall EORTC QLQ\u2011C30 score. The trial reports no significant difference in the overall QoL assessment, with significance observed only for individual symptoms (insomnia, dyspnea). According to FDA guidance, a symptom\u2011specific improvement does not satisfy a superiority claim for the designated endpoint without overall significance.", "citations": [{"title": "Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 5227, "endpoint_id": 5, "truth": 0, "pred": 0, "blended_prob": 0.42255000000000004, "llm_prob": 0.22, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": null, "flags": {"red": [], "yellow": ["Limited direct citation of trial results; inference based on summary data not present in retrieved sources."], "green": ["Primary endpoint (EFS) is a standard, clinically meaningful outcome in oncology trials."]}, "rationale": "The randomized phase II trial enrolled 139 RR\u2011ES patients and reported a posterior probability of 87% that IFOS improves EFS versus CE, implying only a 13% chance that CE is superior; thus the investigational regimen does not meet the decision rule favoring a hazard ratio >1 for CE. The study uses a Bayesian framework and a standard primary endpoint (EFS), but the modest sample size and lack of direct citation limit confidence.", "citations": [{"title": "Clinical Trial Design and Drug Approval in Oncology | JADPRO", "url": "https://doi.org/10.6004/jadpro.2020.11.7.7"}, {"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 3742, "endpoint_id": 194, "truth": 1, "pred": 1, "blended_prob": 0.873448275862069, "llm_prob": 0.95, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target vegfr, pd-1 not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The trial met its predefined Simon two\u2011stage criterion: 5 confirmed partial responses were observed among 26 evaluable patients, exceeding the >4 responses required for a positive primary BOR endpoint. The study was declared positive for the primary endpoint in the abstract.", "citations": [{"title": "NCT04209660 \u2013 Lenalidomide plus Pembrolizumab in Non\u2011ACC Salivary Gland Cancer", "url": "http://www.clinicaltrials.gov/ct2/show/NCT04209660"}]}
{"abstract_id": 4860, "endpoint_id": 302, "truth": 1, "pred": 1, "blended_prob": 0.9015, "llm_prob": 0.94, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target gut microflora and metabolites not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The randomized trial (n=94) compared ICI+chemo with and without Gegen Qinlian Tablets. The primary endpoint incidence of irAEs was 31.91% vs 59.57% (p=0.007), meeting the pre\u2011specified significance threshold (p\u202f<\u202f0.05). Sample size and randomization are adequate for detecting this difference.", "citations": []}
{"abstract_id": 1372, "endpoint_id": 257, "truth": 1, "pred": 1, "blended_prob": 0.6950000000000001, "llm_prob": 0.7, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target ctla-4 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Evidence for tolerability (absence of DLTs) is not present in the retrieved external snippets; reliance is on trial description."], "green": []}, "rationale": "The trial description states that the first three dose\u2011escalation cohorts were completed and no dose\u2011limiting toxicities were reported, satisfying the tolerability decision rule of absence of DLTs. However, no external retrieved evidence corroborates this claim, reducing confidence.", "citations": []}
{"abstract_id": 2892, "endpoint_id": 126, "truth": 1, "pred": 1, "blended_prob": 0.722, "llm_prob": 0.62, "base_prob": 0.875, "base_note": "Base rate from phase_3_plus / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for superiority of NIVO+IPI over SUN on DOR is based on trial details not present in the retrieved external snippets; direct quantitative support is limited."], "green": []}, "rationale": "The trial reports a median duration of response of 76 months for NIVO+IPI versus 25 months for SUN in the ITT population, with higher 96\u2011month DOR probabilities, indicating longer DOR with the investigational regimen. However, the retrieved external evidence only provides general definitions of DOR and does not contain the specific trial data, reducing confidence.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 2882, "endpoint_id": 134, "truth": 0, "pred": 1, "blended_prob": 0.8224347826086956, "llm_prob": 0.82, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["citation for the Trop2 p\u2011value is only from the trial abstract, not from independent external sources"], "green": []}, "rationale": "The exploratory endpoint examined the association of Trop2 expression with ypT0 response. The trial reported a non\u2011significant p\u2011value of 0.15 for Trop2, which exceeds the predefined significance threshold of 0.05, indicating the hypothesis is not supported despite the study\u2019s prospective design and adequate sample for an exploratory analysis.", "citations": [{"title": "SURE-02 (NCT05535218) interim results", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05535218"}]}
{"abstract_id": 1941, "endpoint_id": 109, "truth": 1, "pred": 1, "blended_prob": 0.845, "llm_prob": 0.95, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The downstaging (ypStage 0\u2011I) rate was 65.9% with mFOLFOXIRI+AK104 versus 41.5% with mFOLFOX6 in the mITT analysis, and the reported p\u2011value for this comparison (A vs C) was 0.026, which meets the pre\u2011specified superiority criterion of p\u202f<\u202f0.05.", "citations": [{"title": "OPTICAL\u20112 trial \u2013 Pathologic outcome and surgical parameters", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05571644"}]}
{"abstract_id": 3925, "endpoint_id": 202, "truth": 1, "pred": 1, "blended_prob": 0.7861176470588235, "llm_prob": 0.82, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cyp3a not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size (n=31) may limit robustness"], "green": []}, "rationale": "The trial reports a statistically significant difference in AUC(0\u201324) between the two arms (p=0.002), which meets the predefined decision rule of p<0.05. Although the sample size is modest, the p\u2011value is well below the threshold, supporting a positive finding for this exploratory pharmacokinetic endpoint.", "citations": []}
{"abstract_id": 4860, "endpoint_id": 301, "truth": 1, "pred": 1, "blended_prob": 0.7441176470588236, "llm_prob": 0.75, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target gut microflora and metabolites not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["exploratory endpoint; biomarker tier yellow; significance based on internal trial data only"], "green": []}, "rationale": "The trial reports a p\u2011value of 0.019 for differences in gut microbiota composition between baseline and after treatment, which meets the predefined significance threshold of p\u202f<\u202f0.05 for this exploratory endpoint, supporting a positive finding despite the exploratory nature and limited external validation.", "citations": []}
{"abstract_id": 5052, "endpoint_id": 253, "truth": 1, "pred": 1, "blended_prob": 0.855448275862069, "llm_prob": 0.92, "base_prob": 0.7586206896551724, "base_note": "Base rate from phase_2 / primary (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": ["Evidence for the primary endpoint outcome relies on trial description rather than independent retrieved sources."], "green": []}, "rationale": "The single\u2011arm phase\u202fII study enrolled 22 patients, with 19 evaluable. Twelve of these (63%) remained on sonidegib at 12\u202fmonths, exceeding the predefined 60% threshold, indicating the primary endpoint was met despite the small sample size.", "citations": []}
{"abstract_id": 1325, "endpoint_id": 89, "truth": 0, "pred": 1, "blended_prob": 0.8775000000000001, "llm_prob": 0.9, "base_prob": 0.84375, "base_note": "Base rate from unknown / primary (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target pd-l1 and tigit not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["Primary endpoint outcome (MTD not determined) is not directly supported by the retrieved citations; evidence is limited to trial description."], "green": []}, "rationale": "The phase 1a dose\u2011escalation study enrolled 9 patients across four dose levels and observed one dose\u2011limiting toxicity (grade 3 CRS) at 5\u202fmg/kg, but the investigators explicitly reported that the maximum tolerated dose was not determined, indicating the primary endpoint was not met.", "citations": [{"title": "iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics", "url": "https://recist.eortc.org/recist/wp-content/uploads/sites/4/2017/03/Manuscript_IRECIST_Lancet-Oncology_Seymour-et-al_revision_FINAL_clean_nov25.pdf"}]}
{"abstract_id": 1469, "endpoint_id": 265, "truth": 1, "pred": 1, "blended_prob": 0.7237058823529413, "llm_prob": 0.85, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [{"name": "refractory_population", "factor": 0.9, "reason": "Refractory/relapsed population often has lower success.", "flag": "yellow"}], "biomarker": {"level": "yellow", "reason": "Target programmed cell death-1 (pd-1) not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size (n=10 evaluable) and exploratory endpoint"], "green": ["endpoint result aligns with reported data (no HIV\u2011VL change)"]}, "rationale": "The single\u2011arm phase 1b study of dostarlimab in cART\u2011refractory KS reported that HIV viral load remained unchanged at cycle 4, satisfying the decision rule of no significant HIV\u2011VL change. Although the sample is limited (10 evaluable patients) and the endpoint is exploratory, the observed stability of HIV\u2011VL directly supports the endpoint outcome.", "citations": [{"title": "Starkap (NCT05646082) \u2013 HIV\u2011VL unchanged", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05646082"}]}
{"abstract_id": 3925, "endpoint_id": 209, "truth": 1, "pred": 1, "blended_prob": 0.6661176470588235, "llm_prob": 0.62, "base_prob": 0.7352941176470589, "base_note": "Base rate from unknown / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cyp3a not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size; exploratory endpoint"], "green": []}, "rationale": "The study reports no treatment\u2011related deaths in either arm, satisfying the decision rule of absence of treatment\u2011related death. However, the endpoint is exploratory and the trial enrolled only 31 patients, limiting robustness of the safety conclusion.", "citations": [{"title": "Cancer Drug Approval Endpoints \u2013 FDA Guidance", "url": "https://www.fda.gov/media/71195/download"}]}
{"abstract_id": 390, "endpoint_id": 24, "truth": 1, "pred": 1, "blended_prob": 0.7984347826086957, "llm_prob": 0.78, "base_prob": 0.8260869565217391, "base_note": "Base rate from phase_2 / exploratory (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-l1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Evidence for the MLR\u2011OS correlation is only from the trial abstract; no independent retrieved source was provided."], "green": []}, "rationale": "The phase\u20112 single\u2011arm study of pembrolizumab\u202f+\u202fnab\u2011paclitaxel in 50 mTNBC patients reported a statistically significant inverse correlation between baseline monocyte\u2011to\u2011lymphocyte ratio and overall survival (R\u202f=\u202f\u20110.46, p\u202f=\u202f0.00087), meeting the predefined p\u202f<\u202f0.05 decision rule despite the modest sample size.", "citations": []}
{"abstract_id": 2877, "endpoint_id": 132, "truth": 1, "pred": 1, "blended_prob": 0.722, "llm_prob": 0.62, "base_prob": 0.875, "base_note": "Base rate from phase_3_plus / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "green", "reason": "Target pd-1 has established approvals; lowers risk."}, "flags": {"red": [], "yellow": ["Safety conclusion not directly supported by retrieved external citations"], "green": []}, "rationale": "The phase\u20113, double\u2011blind, placebo\u2011controlled KEYNOTE\u2011564 trial enrolled 994 patients and collected serious treatment\u2011related adverse events throughout and after treatment. The report states that no new serious treatment\u2011related adverse events or safety signals were observed over \u22653\u202fyears of follow\u2011up, satisfying the decision rule of absence of new safety signals.", "citations": []}
{"abstract_id": 3925, "endpoint_id": 208, "truth": 0, "pred": 1, "blended_prob": 0.785, "llm_prob": 0.85, "base_prob": 0.6875, "base_note": "Base rate from unknown / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": {"level": "yellow", "reason": "Target cyp3a not recognized as established biomarker; uncertain risk."}, "flags": {"red": [], "yellow": ["small sample size"], "green": []}, "rationale": "The trial compared ORR between VEN 50\u202fmg\u202f+\u202fposaconazole (n=20) and VEN 400\u202fmg (n=11) and reported ORR of 80% vs 81.8% with a p\u2011value of 1.0, which does not meet the pre\u2011specified significance threshold of p\u202f<\u202f0.05.", "citations": [{"title": "Clinical Endpoints in Oncology \u2013 A Primer", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8085844/"}]}
{"abstract_id": 3679, "endpoint_id": 191, "truth": 1, "pred": 1, "blended_prob": 0.8499999999999999, "llm_prob": 0.95, "base_prob": 0.7, "base_note": "Base rate from phase_2 / not_stated (Laplace-smoothed)", "penalties": [], "biomarker": null, "flags": {"red": [], "yellow": [], "green": []}, "rationale": "The randomized phase\u20112 trial enrolled 150 patients (75 per arm) and reported an overall response rate after neoadjuvant treatment of 94.7% vs 85.3% (p\u202f=\u202f0.042). This p\u2011value is below the pre\u2011specified superiority threshold of 0.05, indicating the toripalimab\u2011containing regimen meets the decision rule for superiority on the ORR endpoint.", "citations": [{"title": "NCT05340270 trial abstract", "url": "http://www.clinicaltrials.gov/ct2/show/NCT05340270"}]}
